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Background: The acute treatment of stroke and transient ischaemic attack (TIA) is
changing and imaging is central to the diagnosis and treatment of these patients. The
hypothesis of this study is that simple CT and MRI baseline characteristics can be
reliably acquired in acute ischemic stroke patients and can be used to predict clinical
outcome in acute stroke patients, minor stroke patients and TIA patients.
Methods: In a cohort of acute ischemic stroke and TIA patients we looked at the
reliability of imaging parameters and how they related to clinical outcome. We tested
the hypothesis that the Alberta Stroke Program Early CT Score (ASPECTS) is
reliable in real time and that using the ASPECTS scale to assess CT angiography
source images would better predict final infarct than CT alone. We also assessed the
reliability of quantifying mismatch between DWI and PWI on MRI with the human
eye. We also hypothesized that we could predict which minor stroke (NIHSS< 3)
and TIA patients would have recurrent clinical or MRI events using a combination of
base line diffusion weighted MRI (DWI), perfusion weighted MRI (PWI) and MR
angiography techniques.
Results: Inter-observer agreement between real time and expert ASPECTS was
substantial; kw=0.69 (95%CI 0.59-0.79). Using a follow up ASPECTS as the final
infarct size, we found that CTA-SI gives a more accurate estimate of tissue that is at
risk of infarcting than does aNCCT alone. Visual assessment of DWI-PWI mismatch
had an inter-rater reliability of 0.68 (95% CI: 0.52 to 1.0; SEM=21.6%) and an intra-
rater reliability of 0.80 (95% CI: 0.47 to 1.0; SEM=16.9%).
10
The 90-day risks, adjusted for baseline characteristics of minor stroke and
TIA patients having a recurrent clinical event, were 4.3% (no DWI lesion), 10.8%
(DWI lesion, no vessel occlusion), and 32.6% (DWI lesion and vessel occlusion),
respectively (p=0.02). The percentages of patients who were functionally dependent
at 90 days in the three groups were; 1.9%, 6.2% and 21.0% respectively (p=0.04).
9.8% (CI95 5.5-15.9) of minor stroke and TIA patients had MR evidence of recurrent
lesions on their MRI at 30days. Increasing lesion number at baseline was associated
with recurrent imaging events. We identified that 34% of TIA patients show
evidence of perfusion abnormalities on an acute MRI.
Discussion: We found that non contrast CT ASPECTS was reliable when applied in
real time. CTA-SI ASPECTS has a greater sensitivity to ischaemic changes and more
accurately identifies the volume of tissue that will ultimately infarct compared to non
contrast CT alone. We found that quantifying DWI-PWI mismatch using the human
eye is reproducible, but not consistent among observers. The margin of error between
raters was large and this may compromise its use for clinical trial enrollment. The
presence of a DWI lesion and a vessel occlusion on an MRI among patients
presenting acutely with a TIA or minor stroke is predictive of an increased risk of a
future stroke and of subsequent functional dependence. Minor stroke and TIA are
associated with a 10% risk of new lesions on MRI and the risk of new lesions was
increased with increasing number of baseline lesions. A high proportion of TIA
patients show a perfusion abnormality despite having their neurological symptoms
completely resolved. Further work is needed on larger populations of patients to see
if the imaging abnormalities identified in this work are predictive of clinical outcome
and to see if these results can be replicated.
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Chapter 1: INTRODUCTION and LITERATURE
REVIEW
Ischaemic stroke is currently the fourth leading cause of death in Canada and
leading cause of adult disability.1 In a developed country, the annual incidence of
first stroke is 1800 per 1 million population, while the incidence of transient
ischaemic attacks (TIA) is 500 per 1 million.2,3,4'5'6 Despite this being a common
disease with devastating consequences there currently is a tremendous lack of
effective acute treatment interventions for iscaemic stroke and TIA patients.
Numerous neuroprotective agents have been studied in clinical trials, but none have
proven efficacious. Intravenous tissue plasminogen activator (tPA) remains the only
drug and route of administration approved in North America for acute stroke
treatment based on the results of the NINDS tPA trials7 and is recommended in all
disabling ischaemic stroke patients fulfilling the clinical criteria of the NINDS tPA
study.8 Eight stroke patients must be treated to "cure" one additional patient of any
residual clinical disability. The narrow therapeutic time window of under three hours
from symptom onset, has limited the utility of this therapy in clinical practice. A
recent evaluation of tPA use in Medicare patients in the United States revealed only
1.7% of all strokes were treated with this therapy.9 Efforts to improve pre-hospital
delivery systems can have some impact on percentage treated but the vast majority of
ischaemic stroke patients will never be eligible based on current inclusion criteria.10
Work has shown that for a variety of reasons, for every one patient treated with tPA,
11 patients are excluded from therapy even if they present within 3 hours of onset. At
foothills medical centre it was identified that 27% of stroke patients arrived in the
emergency department within three hours from symptom onset. However a majority
of these <3 hour stroke patients were excluded from therapy because symptoms were
deemed too mild (13.1%) or patient was felt to be clinically improving (18.2%).
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Tragically, a significant percentage of these patients deteriorated in hospital resulting
in dependence or death.12 Transient ischaemic attack (TIA) patients are at
particularly high risk for recurrent disabling ischaemic events (5% within 48 hours)
early after symptom onset yet there is no reliable method of identifying or preventing
such events.13
Ischaemic stroke and TIA is a heterogeneous disease with many factors
influencing outcome. New approaches are needed to target a larger population of
stroke and TIA patients with the aim to prevent recurrent events and limit disability.
Recently several senior stroke experts urged the further development of
neurovascular imaging to further refine the population of patients that can be
treated.14 Stroke clinical trials to date have largely ignored the potential of
neurovascular imaging to best identify appropriate target populations. Neurovascular
imaging techniques offer such hope by providing a "window" to the ischaemic brain
and intracranial vasculature. Clinical factors such as age, gender, stroke severity and
vascular risk factors alone have proven limited in predicting outcome.15
1.1. Mechanisms of Ischaemic Stroke and Transient
Ischemic Attack's
Approximately 95% of ischemic stroke and TIA's are caused by small vessel
disease, cardioembolism and atheroembolic events.16 Finding a cause for the
ischaemic stroke is important since it allow any potential causes to be treated. For
example atrial fibrillation is a common and important cause of cardioembolic stroke
since it is treatable with anticoagulation; internal carotid artery stenosis is an
important cause if atheroembolic events and again is potentially treatable with
14
carotid endarterectomy. Small vessel disease generally causes "lacunar" syndromes
which are caused by disease of the small intracranial perforating arteries.
Cardioembolic strokes are caused by a variety of different sources including atrial
fibrillation, infective endocarditis, prosthetic heart valves and recent myocardial
infarction.
1.1.1. Pathophysiology of ischemic stroke
The pathophysiology of acute ischemic stroke involves an event that causes a
reduction in cerebral blood flow and then the changes that arise at a molecular level
as a result of the ischemia. The molecular changes leads ultimately lead to ischemic
necrosis (infarction). Ischemic necrosis is a complicated process that is not
completely understood. However, certain components are clear; huge increases in
intracellular calcium occur, together with free radicals and acidosis.
1.1.2. Physiology of cerebral blood flow
The human brain uses glucose as its only substrate for energy metabolism and
requires a constant supply of oxygenated blood containing a constant supply of
glucose to maintain normal function. In normal brain, blood flow is closely coupled
with metabolic demand. If the brain becomes damaged then blood flow and
metabolism become uncoupled and so normal flow does not now necessarily imply
normal metabolism and function. Under normal circumstances, cerebral blood flow
15
is maintained at a relatively constant level, irrespective of the cerebral perfusion
pressure. This is called autoregulation. When the brain has been damaged by
ischemia, autoregulation is less effective and CBF more closely follows changes in
systemic arterial pressure. This is important in mild ischemia, where reductions in
CBF from above 20ml/100g/min which is sufficient to sustain brain function, to
lethal levels below 10ml/100g/min17.
When cerebral perfusion pressure falls, intracranial arteries dilate to maintain
cerebral blood flow. This results in an increase in cerebral blood volume (CBV).
When vasodilatation is maximal, further falls in perfusion pressure result in a fall in
the CBF:CBV ratio and an increase in the oxygen extraction fraction to maintain
tissue oxygenation. When the oxygen extraction fraction is maximal, further falls in
perfusion pressure lead to a reduction in the cerebral metabolic rate of oxygen and
the symptoms of cerebral ischemia.
1.1.3. Penumbra and critical flow thresholds
As cerebral blood flow drops, a critical threshold is reached where the normal
electrical activity of neurons is suppressed. If blood flow continues to fall further
then another threshold is reached when cell necrosis begins18. Cells in between these
2 states are considered to be in the "ischemic penumbra" - i.e. they may not be
functioning, but they are still alive and could either survive or die19'20. The ischemic
penumbra can be defined as an area of severely ischemic, functionally impaired, but
surviving brain tissue which is at risk of infarction but can be saved, if it is
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reperfused before it is irreversibly damaged.21 If no reperfusion occurs then the
penumbra will be progressively recruited until the maximum infarct is reached.
When the CBF falls to below about 20mL/100g of brain per minute the
neuronal electrical activity ceases and the first threshold is reached22. When blood
flow falls to about lOml/lOOg of brain per minute this is the beginning of irreversible
cell damage. This is the point at which membrane failure occurs23.
1.2. Thrombolysis outside the 3 hours time window- "the
tissue window"
Most ischaemic stroke patients are not eligible for tPA because they arrive
after the three hour window.8 However, due to the experimental evidence described
above regarding the ischemic penumbra there is much discussion regarding use of
imaging characteristics rather than time as a barrier to treatment. There is increasing
clinical evidence that these "late" patients may still derive benefit from thrombolysis
at later time points.24'25'26 Angioplasty and stenting of critical carotid artery
narrowing has been associated with dramatic clinical improvement more than 10
hours after symptom onset.27 Numerous reports of dramatic clinical improvement
have been identified in patients with basilar artery occlusion, who are treated with
intra-arterial thrombolysis at late time points. These are patients with acute cerebral
ischaemia in whom brain tissue is at risk of infarction but permanent damage has not
yet occurred. Depth of ischaemia and length of ischaemia are both critical in
determining when and how much brain will infarct after cerebral vascular
occlusion28. Patients with strokes are heterogeneous and the interactions of multiple
variables will in turn affect the depth of ischaemia or the susceptibility of tissue to
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damage (e.g. site of occlusion, collateral supply, blood pressure, body temperature,
glucose and age)29. In addition, different tissues within the brain, e.g. grey and white
matter, cortex and subcortex, have different thresholds of ischaemia at which
infarction is inevitable30. The challenge, in the clinical setting, is to find surrogate
markers that reflect the degree of ischaemia and to therefore identify patients with a
baseline "tissue window" (tissue at risk which has not yet infarcted) that allows
intervention. This would allow the treatment of a large number of ischaemic stroke
patients who currently are ineligible for thrombolysis because they are beyond the
"magical" 3 hour time window. Thrombolysis carries with it a risk of hemorrhage
and may be more of an issue when attempting to prolong the window for
thrombolysis. New research has examined some of the MR parameters associated
with hemorrhage.3' A recent study of patients awakening with symptoms identified
that 10% had significant regions of ischaemic tissue at risk based on MRI parameters
which could represent a patient population which is salvageable with intervention.32
Studies such as these allow us to further refine the target population for
thrombolysis.
1.3. Minor Stroke and TIA
Time is critical to the diagnosis and management of cerebrovascular disease26.
The classical definitions of stroke and transient ischaemic attack (TIA) are arbitrarily
set around duration of focal neurological deficit more or less than 24 hours
respectively33. Ischaemic stroke is a focal neurological deficit of vascular origin in
which the deficits last at least 24 hours. By contrast a transient Ischemic Attack
(TIA) is a clinical syndrome characterized by an acute loss of focal neurological
function of vascular origin. Those with disabling ischaemic stroke presenting within
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three hours of onset are eligible for treatment with thrombolysis7. Systems of care
have been streamlined to maximize the utilization of thrombolysis with the end result
that patients with both disabling and non-disabling events are presenting well within
the 24-hour window that is required to make the classical definitions12. The key
question now is how to triage those with non-disabling deficits more effectively.
It has long been realized that a previous TIA or minor stroke confers a higher
risk of recurrent stroke34 with the conclusion drawn by some that the difference
between the two is probably redundant.35-36 The short-term, 90-day, risk of stroke
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following a TIA is between 10 and 20 percent. ' ' Among patients with mild
stroke, deemed too mild for thrombolytic therapy, one third are dependent or dead at
hospital discharge.12 Half of the risk of recurrent stroke is accrued within the first 48
to 72 hours of the event13, hence the necessary urgency to identify those at immediate
risk.
For many years it was presumed that TIA's were associated with complete
resolution of brain ischaemia leaving no permanent brain injury.39'40 However, since
the original definitions of TIA and stroke were established, advances in
neuroimaging have occurred. A substantial proportion of patients with TIAs,
according to the classical definition, have injury observed on diffusion weighted
imaging (DWI) of the brain on magnetic resonance imaging (MRI).41'42'43'44'45
Patients with prolonged duration of ischaemia44'45 or having speech or motor
deficits42 are more likely to demonstrate injury on brain imaging. However, currently
no group has looked to see if perfusion abnormalities are present in TIA patients
despite resolution of symptoms. No risk stratification model exists that is specific or
sensitive enough to predict those at the highest risk of recurrence. Johnson et al13
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proposed clinical risk factors including diabetes and age greater than 60 years old, to
identify those at the highest risk, but these have not been prospectively validated.
They are essentially the same as those that have been proposed previously, which
have failed previous validation efforts. 13-46'47 it is therefore not clear how to triage
this group of patients accurately, to reflect the risk of recurrence according to their
clinical presentation or personal characteristics. Proposed causes of clinical
deterioration or recurrent events have been suggested which include: recurrent
emboli48, hemodynamic failure from persistent occlusion of the extracranial49 or
intracranial arteries50, rethrombosis51'52'53 or reocclusion.54 Persistent occlusion and
reocclusions of the intracranial and extracranial vessels can be identified by TCD,
CTA or MRA. Identifying a high risk group among minor stroke and TIA patients
could lead to randomized trials in a new therapeutic target population.
1.4. Non contrast CT and CT bolus techniques
Computed tomography (CT) is currently the modality of first choice for
imaging patients with acute stroke. Although magnetic resonance imaging (MRI)
has uncovered considerable information on the process of ischaemic infarction, most
patients with a stroke present to community hospitals without acutely available MRI
55. MRI is also prohibited until contraindications can be ruled out. Claustrophobia,
motion artifact, longer scan time, inability to use standard treatment or monitoring
equipment make MRI a difficult technique to rely upon in a high volume stroke
center. Although non contrast CT was initially used to exclude intracranial
hemorrhage and other non-stroke pathologies, advanced CT techniques are
increasingly recognized as a modality to characterize early signs of ischaemia.56'57
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Imaging techniques that improve patient selection for acute stroke treatment are vital.
With the use of multi-slice CT scanners, the potential information available from a
CT scan has increased.58 CT angiography and CT perfusion techniques can refine the
current clinical criteria for patient selection for thrombolysis.7
The European Co-operative Acute Stroke Study (ECASS)59 trials first
recognized the importance of assessing the CT scan for early ischaemic changes in
an attempt to predict benefit from intravenous thrombolysis. The ECASS I protocol
intended to exclude patients with extensive changes of ischaemic cerebral injury on
the CT scan, defined as >33% of the MCA territory. Unfortunately the local
investigators missed 17.4% of patients with >33% of the MCA territory affected. In
these patients there was evidence of large ischaemic change on the CT that had been
overlooked by the local investigators. Early ischaemic changes are subtle and the
reliability of assessing the extent ofCT infarction has been relatively poor.57'60'61,62
Despite these limitations this method of semi-quantifying early ischaemic changes in
the middle cerebral artery territory has been used in future thrombolytic trials to
exclude patients with large areas of brain already infarcted.
Non contrast CT (NCCT) findings can predict vascular occlusion and still
viable ischaemic brain63'64. The Alberta Stroke Program Early CT Score (ASPECTS)
was devised by the Calgary stroke program to provide a systematic approach for
assessing early ischaemic changes in regions of the middle cerebral artery (MCA)
territory65. Using this score we achieved good agreement among CT observers
(Kappa 0.71-0.89 when the affected hemisphere was known)66. By systematically
quantifying early CT ischaemia we were able to predict functional outcome and the
risk of symptomatic hemorrhage in tPA treated stroke patients65. The advantage of
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ASPECTS is that it combines a semi-quantitative estimate of volume with
localization by simply weighting smaller volumes in the basal ganglia and internal
capsule equally with larger volumes of brain designated Ml through M6. Details of
ASPECTS scoring is outlined in Pexman et al.67 Recent work using ASPECTS to
retrospectively score the scans from the PROACT-II study (patients randomized
within 6 hours of symptoms to intra-arterial thrombolysis with recombinant pro-
urokinase or control) showed that ischaemic stroke patients with a baseline
ASPECTS > 7 were three times more likely to have an independent functional
outcome with thrombolytic treatment compared to control. Patients with a baseline
ASPECTS <7 were less likely to benefit from treatment.56
Increased density of vascular structures known as hyperdense artery signs
have also become valuable in identifying arterial occlusion.68 The hyperdense middle
cerebral artery sign (HMCAS) correlates well with middle cerebral artery (MCA)
occlusion based on angiography69 and the recently described MCA "dot" sign70
correlates with distal MCA occlusion identified by conventional angiography.71
Newer CT bolus tracking techniques including CT angiography and CT
perfusion (CTP) also are available but require the use of nonionic intravenous
contrast. The sensitivity and specificity of CT angiography is excellent for
diagnosing large vessel occlusion.72 Source images from CT angiography (CTA-SI)
can be rapidly obtained with minimal delays after a non-contrast CT (NCCT) in the
Emergency Room.73,74'75 Although CTA has been shown to have value in identifying
vessel occlusion, CTA source images (CTA-SI) also have value in the assessment of
tissue status. The administration of a single contrast bolus can be used to
simultaneously acquire both CT angiographic images (CTA) of the complete
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neurovascular system (arch-to-vertex) and whole brain "perfused" blood volume-
weighted CTA source images (CTA-SI). "Perfused" reflects the fact that only
contrast material that reaches the imaged voxels during scan acquisition contributes
to measured blood volume. Thus, although theoretically CTA-SI should be entirely
blood volume-weighted, a component of flow weighting may also exist. The bolus is
given with timing that should allow visualization of only the arterial phase and not
the venous phase. Schramm et al found that the combination of CT, CTA and CTA-
SI was comparable to that of an MR-DWI.76 CTA-SI can also be useful in predicting
final infarct volume.77'78 Brain tissue with a low cerebral blood volume appears
hypodense on CTA-SI, thus effectively delineating regions of ischaemia.77 Currently
there are only a few stroke clinical outcome studies using CT angiography and
quantitative CTP79'80 although recent work on a small number of patients suggests
that CT perfusion and NCCT can be equivalent to DWI/PWI imaging in identifying
potentially salvageable tissue.81 Further studies are needed in this area.
1.5. Multimodal Magnetic Resonance Imaging (mMRI)
Fast MR imaging is possible in the acute stroke setting. Multi-modal MR
imaging can provide information on the status of brain parenchyma, vasculature and
cerebral perfusion. Diffusion-weighted imaging (DWI) and the apparent diffusion
coefficient (ADC) maps derived from them detect change in the local diffusion of
water and are sensitive to changes of hyperacute ischaemia82. This sequence analyzes
water movement within the brain tissue at the molecular level. With infarction of
brain tissue, normal water movement is restricted and this abnormality can be
visualized on DWI scan images. The diffusion data can be presented as signal
intensity or as an image map of the apparent diffusion coefficient (ADC). Calculation
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of the ADC requires 2 or more acquisitions with different diffusion weightings. A
low ADC corresponds to high signal intensity (restricted diffusion), and a high ADC
to low signal intensity (as would be seen with T2 shine through). In the setting of
acute cerebral ischemia, if the cerebral blood flow is lowered to 15-20
ml/lOOgm/min, the cell membrane ion pump fails and excess sodium enters the cell,
which is followed by a net movement ofwater from the extracellular to intracellular
compartment and cytotoxic edema. Diffusion of the intracellular water molecules is
restricted by the cell membranes. The restricted diffusion results in a decreased ADC
and increased signal intensity on density-weighted images. Conventional anatomical
T2-weighted and FLAIR imaging sequences allow visualization of late tissue
damage. Similarly but at lower spatial resolution the b=0 diffusion sequence acquired
during DWI is T2 weighted and has the advantage that it is essentially co-registered
with the other diffusion images and can be rapidly acquired. Lesion volume changes
over time but the initial volume of the stroke on diffusion imaging correlates well
with late infarct volume on MR.8 ,84 There is a correlation between initial diffusion-
weighted volume and NIHSS at later time points85 (r=0.86), although clinical
outcome is dependent on more than just lesion volume.
Dynamic-susceptibility contrast enhanced perfusion-weighted imaging (PW1)
requires a bolus injection of gadolinium contrast.86 Currently this is used to provide
information on relative cerebral blood flow (rCBF), cerebral blood volume (rCBV)
and mean transit time (rMTT) and with more complex post-processing can yield
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quantified perfusion measures. ' ' Findings of perfusion-diffusion mismatch
(volume of the MTT perfusion deficit larger than the diffusion abnormality early
after stroke symptom onset) have led to investigation of the concept of an "ischaemic
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penumbra". This is an area of tissue surrounding the core of an infarct that has
reduced blood flow but is still potentially viable,90'91 which may be salvageable if
blood flow is rapidly re-established.92 A number of studies have explored perfusion-
diffusion mismatches at various time points to trace the natural history of ischaemic
lesions93'94'95'96'97'98'99. These studies show that mismatches have some predictive
ability for defining final outcome when used in acute stroke100. Not all penumbral
areas go on to infarct at follow-up and some DWI lesions "grow" beyond the initial
perfusion deficit. Currently there are clinical trials looking at response to
thrombolysis in relation to mismatch101'102 and some groups are using mismatch to
select patients for thrombolysis.103 Visual estimation of the three-dimensional (3D)
mismatch is difficult and it is not clear whether the human eye can reliably identify
patients with mismatch.
3D time-of-flight MR angiography (MRA) allows visualization of the site of
vascular occlusions. We have shown that training improves the reliability ofMRA
interpretation but that it correlates well with conventional angiography.104 In
addition the use of post-contrast MRA better delineates arterial patency over




The hypothesis of this study is that simple CT and MRI baseline characteristics
can be reliably acquired in acute ischemic stroke patients and can be used to predict
clinical outcome in acute stroke patients, minor stroke patients and TIA patients.
Specific hypotheses include:
1. That the use of ASPECTS to quantify the amount of early ischaemic damage
on a NCCT in every day clinical use (real time) is reliable. This has been
shown to be of use in the prognosis of stroke patients', however the scale will
not be useful until it can be performed in real time.
2. That the ASPECTS score can reliably be scored on CTA-SI and will better
predict final infarct volume than ASPECTS based on the NCCT alone.
3. Mismatch between PWI and DWI is being increasingly used to select patients
for thrombolysis. We hypothesized that the human eye could not reliably
identify mismatch on MRI.
4. That the presence of lesions on diffusion weighted imaging and vessel
occlusion on intracranial MRA in minor stroke and TIA patients would
predict clinical outcome and recurrent events.
5. That using simple patient baseline clinical and MRI characteristics it is
possible to predict recurrent MRI events (clinically symptomatic or
asymptomatic).
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Chapter 2: GENERAL METHODS
This study is a prospective cohort study assessing non-contrast CT and multi¬
modal MRI in acute stroke and TIA patients. This chapter describes the methods for
the overall data collection. Specific projects within the overall study are described in
the chapters that follow.
2.1. Inclusion Criteria
Patients presenting to the Foothills Medical Centre, emergency department
with:
Persistent focal neurological deficit or transient ischaemic attack consisting of
hemiparesis or aphasia lasting >5 minutes
Age > 18
< 12 hours from time last seen normal
Premorbid status modified Rankin 2 or less
Baseline imaging performed within 3 hours of hospital arrival in stroke patients and
within 24 hours of hospital arrival in TIA patients.
When tPA is given all imaging modalities will be initiated prior to or early into tPA
infusion.
2.2. Exclusion criteria
CT scan evidence of hemorrhage or tumor
Classic migraine features (fortification spectra, zigzag lines, march of sensory
symptoms)
Hypoglycemia (serum glucose <2.0 mmol/1)
Serious comorbid illness that would result in the patient being unlikely to survive 3
months or contaminate evaluation scales (eg. NYHA IV CHF, metastatic cancer,
severe liver disease) or patient unlikely to be able to meet all follow-up appointments
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Seizure is definitely thought to be cause of deficits
Obvious psychogenic cause of deficits
2.3. Informed Consent
A consent form was reviewed with all eligible patients outlining the risk and
benefits of the study (appendix 1). Consent was also obtained to collect and store
data. If a patient was incapacitated by the stroke and unable to give informed
consent, the next of kin or legal guardian was approached to give consent. If a
subject later was able to consent the consent process was reviewed with that person
to determine whether they wished to continue participating in the study. Patients who
underwent intra-arterial (IA) tPA or any concurrent clinical trial were included.
2.4. Baseline Clinical Data Collection
The following demographic information was collected: age, gender;
handedness, cerebrovascular risk factors, antithrombotic use, other premorbid
disease, time last seen normal, and side of symptoms. See appendix 2. Initial blood
pressure recording at triage, serum glucose, International Normalized Ratio (INR)
and platelet count on admission was collected. IftPA is given, time of bolus and
route(s) of administration were collected. If a patient was enrolled in a therapeutic
clinical trial this was recorded.
A baseline National Institutes of Health Stroke Score (NIHSS)'06 (appendix
3) was performed prior to baseline imaging (other than NCCT). The NCCT is part of
routine clinical practice and often performed before the stroke team is consulted
particularly in the minor stroke and TIA group of patients. The patient or next of kin
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was interviewed to determine the premorbid modified Rankin Scale107'108 (Appendix
4).
2.5. Baseline Imaging and interpretation
2.5.1. Non contrast CT
An investigator blind to MRI information assessed the baseline CT scan. The
investigator had knowledge of the patient's affected side only. A noncontrast CT
scan was performed on the multi-slice CT scanner. The scans were assessed for the
presence of hemorrhage, parenchymal hypoattenuation in the anterior, middle, or
posterior cerebral artery territories and the vertebrobasilar artery distribution, focal
swelling, hyperdense middle cerebral artery (HMCA) sign, and MCA "dot" sign. The
MCA territory was scored using ASPECTS65' 7(appendix 5). CT imaging was
optimized using our standard imaging protocol which optimizes detection of early
ischaemic changes.67 Scans were rated by stroke neurologists trained in ASPECTS.
(Appendix 6)The CT scan was also assessed for ASPECTS prospectively by the
treating physician in real time clinical use.
2.5.2. CT bolus study (CT angiography and CT
perfusion)
When clinically indicated (but not mandated in the study) a CT bolus study
was performed on the multi-slice CT scanner. The CTA was assessed for evidence of
tissue hypodensity and for vascular occlusion or diminished flow.
2.5.3. Multimodal MRI (mMRI)
All patients were screened for contraindications to MRI or to gadolinium
contrast agent before they entered the scanner. The MRI was performed on the 3T
magnet (Signa; General Electric, Waukesha, WI) in the Seaman Family MR
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Research Centre. The sequences acquired were a sagittal T1 localizer, axial DWI,
axial FLAIR, axial T2-weighted, pre-gadolinium contrast time of flight MRA, axial
PWI and post gadolinium contrast time of flight MRA. This set of sequences and the
preparation time took no more than 30 minutes to perform. A power injector was
used to administer contrast agent. The baseline multimodal MRI scan was assessed
by a neuroradiologist blind to CT information. The investigator had knowledge only
of the patient's clinically affected side. A graded assessment of image quality was
made taking into account motion and other artifacts. Information was collected on
the vasculature, the tissue (new and old lesions, white matter disease etc.) and on the
cerebral perfusion (Appendix 7).
2.5.4. Perfusion
Perfusion weighted sequences was used to create relative mean transit time
(rMTT) graphs and maps. The rMTT delay between a region of interest positioned
over the area corresponding to the largest DWI lesion and the mirror-image area on
the unaffected side was recorded. The presence of any rMTT map lesion and its
extent in comparison to the extent of the DWI lesion was recorded. This was
recorded as showing evidence of mismatch or not. The negative enhancement
integral algorithm was used to create a relative cerebral blood volume map. The
presence of any oligemia or hyperemia with respect to the unaffected side was noted
and the presence of mismatch between the extent of oligemia and the DWI lesion
extent was observed.
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2.6. Clinical Follow up
All patients were either admitted to a stroke unit or to a high dependency unit
if intensive care was required. NIHSS score was recorded at 24 hours while in
hospital. NIHSS was also performed at 30 days and 90 days. The 30 day NIHSS and
modified QVSFS (Questionnaire for verifying stroke free status, Appendix 8)109 was
performed at the time of follow-up MRI. All patients were assessed at 3 months post
event and an NIHSS and modified Rankin score was performed. The physician
assessed whether further strokes have occurred, which would impact on the final
outcome scores, using a modified QVSFS. The final diagnosis and TOAST
classification were recorded. The date of any recurrent stroke (ischaemic or
hemorrhagic) or TIA was recorded as well. (Appendix 9)
2.7. Follow up Imaging
MRI was repeated at 1 month (± 2 weeks) post stroke. The MRI protocol
consists of identical sequences to those performed at baseline with the exception of
the perfusion weighted study. If a MRI was not completed or is contraindicated a
NCCT was obtained. The follow-up scan was assessed by an investigator blind to all
baseline information, (appendix 10 for MRI and 11 for CT)
2.8. Storage of data
Clinical and radiological data collected was stored in paper and in electronic
form. The data base used was constructed using Access and allowed queries of all or
part of the database. The database was maintained by me and the accuracy of any
information was verified by me.
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2.9. Statistical analysis
Data analysis is described for each subsection in the individual chapters. I am
indebted to Dr Michael Eliasziw PhD and Dr Michael D. Hill MD for their help with
the statistical analysis.
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Chapter 3: Reliability of ASPECTS performed in real
time
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As described in the introduction ASPECTS is a 10 point scale rating the early
ischaemic changes seen in acute stroke in the middle cerebral artery territory on CT.
Previous studies of ASPECTS have been done with consensus assessment56 or not
prospectively65. In this project we describe the reliability of ASPECTS rated
prospectively by the treating physician as compared to the ASPECTS performed at a
later date by an expert rater.
3.1. Methods
Prospectively 214 patients were recruited into this study. Inclusion criteria
were stroke or transient ischaemic attack (consisting of hemiparesis or aphasia
lasting more than five minutes) that were scanned within 12 hours of last seen well,
were older than 18 years of age and were functionally independent on the modified
Rankin scale (score 2 or less). All patients presenting with the above characteristics
were included, not just middle cerebral artery syndromes. Patient demographics
were recorded at the time of admission to the emergency department. The protocol
was approved by the local institutional ethics review board.
3.1.1. Imaging
Standard non-contrast CT was performed with a 4th generation multi-slice
CT scanner (GE Medical Systems) in the emergency room. The non-contrast CT
scanning technique was as follows: 120kV, 170mA, 2-second scan time, and 5-mm
slice thickness. Coverage was from skull base to vertex with contiguous axial slices
parallel to the inferior orbitomeatal line. A window width of 75-80 HU and window
level of 30-40 HU were used to maximize tissue contrast. Physicians were able to
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alter the window width and leveling as appropriate to maximize the appearance of
ischaemic changes110.
3.1.2. Image Analysis
The ASPECTS was recorded prospectively by the treating physician at the
time ofCT scan. The treating physician (stroke fellow or stroke neurologist
experienced in rating ASPECTS) scored the ASPECTS without knowledge of any
other imaging modalities, but with knowledge of clinical symptoms. At a later point
one of four expert readers (different individual than the treating physician; including
one neuroradiologist, two stroke neurologists and one stroke fellow) rated the
baseline CT scan using ASPECTS. The expert reader was blind to all clinical
information and previous ASPECTS. The expert reader however had knowledge of
the symptom side. Each scan was read by the treating physician and later by one
expert reader.
3.1.3. Statistics
Descriptive statistics were used to evaluate the study population. Inter-rater
reliability between experts was not measured, but the reliability between experts has
been previously shown to be equivalent.66 Agreement between the real-time and
expert ASPECTS rating was assessed using weighted kappa (kw) scores. The
weighting was designed to heavily penalize any difference greater than 1 ASPECTS
point, kw values were interpreted as slight agreement 0.00-0.20, fair agreement 0.21-
0.40, moderate agreement 0.41-0.60, substantial agreement 0.61-0.80 or almost
perfect agreement 0.81-1.00.111
The distribution of ASPECTS scores (real time and expert) was skewed. The
differences between the real-time and expert ASPECTS scores were normally
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distributed. The unit of analysis was the difference between the real time and expert
ASPECTS. Analysis of variance was used to assess the difference between
categories of real time ASPECTS values and the difference between the real time and
expert ASPECTS. Hypothesis testing between groups was adjusted using the
Bonferroni method. Linear regression was used to plot this relationship.
3.2. Results
There were 214 patients included in this study between May 2002 and July
2003; 88 (41%) were female. The median baseline NIHSS was 5 (range 0-32).
Median age was 72.5 (27-91). Fifty-four patients had a transient ischaemic attack by
the current definition39 (NIHSS = 0 at 24 hours). Median time from symptom onset
to CT scan was 152 minutes (range 22-769 minutes).
Inter-observer agreement between real time and expert ASPECTS was
substantial; kw=0.69 (95%CI 0.59-0.79). The mean difference was 0 (SD 1.1). There
was no difference in the reliability if transient ischaemic attack patients were
excluded (kw=0.66, n=160) or if only patients scanned at under 6 hours are
considered (kw=0.68, n=183) or if only stroke patients scanned at under 6 hours are
considered (kw=0.65, n=140).
Trichotomizing the ASPECTS scale into <3 (unfavourable); 3-7 (neutral) and
8-10 (favourable) had no impact on the mean differences between real time and
expert ASPECTS, except when the real time ASPECTS was <3. In this situation the
expert reader was likely to call the scan approximately two ASPECTS points greater
than the treating physician (p=0.007 for 3-7, and p<0.001 for 8-10). There was a
trend towards the treating physician under calling the ischaemic change in the 8-10
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group i.e. the treating physician gives a clinically more favourable score than the
expert. However this did not reach statistical significance (p=0.064). This
relationship was not affected by age, blood glucose or the baseline N1HSS score.
Figure 1 gives a graphic representation of the correlation between the real
time ASPECTS and the difference between the real time ASPECTS and the expert
ASPECTS. The slope of the line suggests that at lower real time ASPECTS ratings,
there is a trend for the treating physician to over-interpret the presence of ischaemic
change. (Figure 2)
3.3. Conclusions
The reliability of rating ischaemic change on the acute stroke CT in routine
clinical practice compared to expert rating has not been previously evaluated. We
have found that ASPECTS is reliable between real time and expert ratings. This is
important because the true significance of a clinical scale is its ability to be used in
routine clinical practice. However, it must be emphasized that this clinical scale is
only useful for the middle cerebral artery territory strokes and not the PCA or ACA.
At higher ASPECTS (>7) scores (favorable scan appearance) the real-time
observer tends to under-call ischaemic change. The effect size is quite small and is
likely to be clinically insignificant. There are many possible reasons for this, but if
this effect is real it is likely due to the physicians wish to treat the patient with
thrombolysis.
At lower ASPECTS (<3) scores (unfavorable scan appearance) the real-time
observer tends to over-call the ischaemic change by nearly two points. The reasons
for this probably reflect a combination of factors including the visual perception
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system's tendency to overestimate boundaries."2 Human factors such as a desire not
to administer thrombolysis may also spur the real-time observer to naturally err
toward lower scores. This effect is possibly an overestimation of the effect due to
the fact there are only 6 patients in this group There was no relationship between
NIHSS and the differences seen between the real time and expert ASPECTS. This
suggests that the real time physician does not overcall ischaemic change due to bias
introduced by knowledge of stroke severity. At the high end of the scale, the
physician may be keen to offer thrombolysis and under-interpret the ischaemic
change. A final reason for disparity in scoring between the real time and expert rating
is that the treating physician often does not have ideal conditions for the rating of
brain CT scan.
A weighted Kappa was used for the statistics since artificially dichotomizing
the results into >7 and <7 would overly penalize a scan that an expert called a 7 and
the treating physician called a 6. A score of ± 1 point on the ASPECTS scale has
been to shown to the expected margin of error66, is felt not to be clinically significant
and would not deter thrombolytic treatment for any given patient. Hence the Kappa
score was weighted to penalize any difference more than ± 1 point. This is a potential
limitation of this study, however to regard scores of 8 or 9 as different may
artificially disadvantage a simple scale.
Our population included patients with transient ischaemic attack and patients
who were imaged between 6 and 12 hours after symptom onset. However removing
these patients from the analysis made no difference to agreement.
The results in our study are limited to stroke neurologists and
neuroradiologists. We did not assess the ability of emergency physicians or trainees
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to rate ASPECTS. This is an important limitation and future work is needed in this
area.
In conclusion we have found that ASPECTS performed in real time is a
reliable method of quantifying the early ischaemic changes of the middle cerebral


























Figure 1: Graphic representation of the real time ASPECTS compared to the
real time ASPECTS- Expert ASPECTS. The slope of the line suggests that at
lower real time ASPECTS ratings, the treating physician is likely to over-call
the presence of ischaemic change. Outside lines show 95% confidence
intervals
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Figure 2: Overcalling in Real time. A, B and C show the representative cuts
from a CT scan performed at 3 hours and 8 minutes after symptom onset on
an acute stroke patient with right hemiparesis and aphasia (NIHSS 16). The
treating physician rated the scan as having an ASPECTS of 4 with regions:
Insula, M2, M3, M4, M5 and M6 rated as abnormal. Later expert review of the
scan rated the scan as having an ASPECTS of 7 with regions: Insula, M2,
and M3 rated as abnormal (MCA dot sign seen on cut A). C, D and E show
the diffusion weighted MR performed 4 hours and 40 minutes after symptom
onset. An evolving infarct is seen in ASPECTS regions; Insula, M2, M3, and
M5 (total score 6).
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4. Chapter 4: ASPECTS on CTA Source Images versus
unenhanced CT: Added value in predicting final infarct
extent and clinical outcome.
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We sought to assess whether the final infarct ASPECTS and clinical outcome
were associated with the acute CTA-SI ASPECTS.
4.1. Subjects and Methods
4.1.1. Patients
We assessed the clinical and imaging information of consecutive patients
with acute ischaemic stroke from two institutions, who had NCCT and CTA (18
patients from Departments of Radiology and Neurology, Massachusetts General
Hospital, Harvard Medical School, Boston and the other 21 from Foothills Hospital
in Calgary). Stroke onset was defined as the time the patient was last seen well.
Exclusion criteria were CT scan evidence of hemorrhage or tumor, hypoglycemia
(serum glucose <2.0 mmol/1), serious comorbid illness that would result in the
patient being unlikely to survive 3 months or contaminate evaluation scales or a
patient who did not complete any follow up imaging due to severe neurological
deterioration, age<18, premorbid status modified Rankin >2 or symptoms suggestive
of a posterior circulation event. Exclusion criteria specific for CTA were, a known
history of contrast medium allergy or any degree of renal failure. Patient
demographics and clinical characteristics were recorded at the time of admission to
the emergency department. All patients received intra-venous or intra-arterial
thrombolysis if appropriate as indicated by their clinical findings. Informed consent
was obtained from the patient or their next of kin and this project was approved by
the local institutional ethics committees of both institutions.
4.1.2. Imaging
Standard NCCT was performed with a multi-slice CT scanner (GE Medical
Systems) in both institutions using 120kV, 170mA, 2-second scan time, and 5-mm
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slice thickness. Coverage was from skull base to vertex with contiguous axial slices
parallel to the inferior orbitomeatal line.
NCCT scanning was followed immediately on the same scanner by CTA
imaging with a helical scan technique. Previous work has shown that this adds
around 10 minutes to the scanning time.77 Acquisitions were obtained following a
single bolus intravenous contrast injection of 90 to 120ml of nonionic contrast into an
ante-cubital vein at 3 to 4 ml/sec with a 20 to 25 sec delay from the start of the
contrast injection to the onset of imaging. The image sequence covered the foramen
magnum to centrum semiovale or vertex with a scan field of view (25.0 cm; 140 kV,
170 mA; Table speed 3.75mm/sec; 2.5mm slice thickness with 2.5mm interval; 1.0
sec per rotation). Source images (CTA-SI) were reconstructed to 1.25mm thickness
at 0.625 mm intervals.
Follow up imaging was performed on all patients. T2-weighted MR imaging
was substituted among patients for whom follow-up NCCT was unavailable. All
follow up imaging was performed at a minimum of 24 hours after symptom onset.
Clinical outcome was assessed by a stroke neurologist using the modified Rankin
Scale during an in-clinic visit. If a patient was unable to return to clinic either the
modified Rankin was completed by telephone or a physician attended the nursing
home to complete the clinical scales. Favorable patient outcome at 90 days was
defined as a modified Rankin score of 0 or 1.
4.1.3. Image analysis
The assignment of an ASPECTS to each patient's image was performed
independently by a neuroradiologist and a stroke neurologist. Both readers were
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experienced in the interpretation ofCT scans in acute stroke. Two other individuals,
a neuroradiologist and a stroke neurologist, interpreted a subset of images for
calculation of inter-rater agreement. Raters were blinded to all clinical information
except for symptom side. The scoring ofNCCT, CTA-SI images and follow up
imaging (NCCT or MR1-FLAIR) were in a random order. Baseline and follow-up
imaging interpretation was spaced over several weeks.
All images were reviewed digitally at a workstation with a large high-
resolution monitor. Care was taken to use optimal width and level settings during
CT image review to maximize the contrast produced by the small attenuation
difference between normal and hypodense brain parenchyma110. NCCT images were
evaluated for evidence of focal parenchymal low attenuation, loss of grey-white
differentiation and sulcal effacement using ASPECTS as previously described67. On
the CTA-SI, regions of relatively diminished contrast enhancement were scored as
abnormal (figure 3). The CTA-SI were viewed at the window and level that allowed
the maximum contrast between normal and ischaemic tissue110. The CTA-SI and
circle of Willis maximum intensity projection reconstructions of the CT angiogram
were evaluated for the presence of occlusion. ASPECTS on MRI was assigned in a
similar manner to NCCT, as previously described.113
4.1.4. Statistical Analyses
The unit of analysis was the mean of the two readers' ASPECTS. A two-
factor repeated measures analysis of variance was used to compare the mean baseline
ASPECTS between NCCT and CTA-SI. In the analysis of variance, the between-
subject factor was the follow-up ASPECTS, categorized as 0 to 3, 4 to 7, and 8 to 10.
The within-subject factor was the baseline ASPECTS, because the NCCT and CTA-
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SI scores were obtained from the same patient's CT scan. Rate ratios (RR) were
used to quantify the relationship between the dichotomized baseline ASPECTS
(categorized as 0-7 versus 8-10) and favorable patient outcome. The chosen cut
point has been previously used as a cut point above which benefit is seen in using
intra-arterial thrombolytic therapy for acute ischaemic stroke patients.56 Inter-rater
agreement in assigning ASPECTS was estimated using an intra-class correlation
coefficient computed from a one-way analysis of variance.
4.2. Results
A total of 39 patients were recruited between May 2002 and May 2003. There
were no adverse events related to the use of the contrast medium. Demographic
results are described in this section as median and the interquartile range is shown.
The median age of the patients was 74 (62 to 81) years and 54% were female. The
median baseline NIHSS was 16 (9 to 22) and 90% of the patients were treated with
tPA. 4 patients were treated with iv/ia therapy, 13 were treated with iv alone and 18
were treated with ia tPA alone. The median time between symptom onset and
imaging was 1.9 (1.2 to 2.5) hours, with 41% of the scans performed within 90
minutes of symptoms. Proximal occlusion (ICA or MCA) on CT was identified in
62% of the patients, M2 occlusion in 18%, and no large vessel occlusion in 20%.
The follow-up scan was performed at a median time of 10 (4 to 34) days. T2-
weighted MR imaging was substituted for follow-up NCCT in 14 (36%) patients.
The overall mean baseline ASPECTS differed by 1.1 (p-value < 0.001).
Figure 4 summarizes the mean differences at each follow-up ASPECTS category.
There was a significantly larger difference of 1.4 between the mean baseline NCCT
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and CTA-SI ASPECTS in patients who had more ischaemic changes (follow-up
ASPECTS = 0 to 3) than a difference of 0.6 in patients who had near-to-normal CT
scans (follow-up ASPECTS = 8 to 10). There were no cases of CTA-SI
overestimating the final infarct size. In 7 of the cases that ultimately had a stroke
(follow-up ASPECTS <10) one reader interpreted the NCCT as normal (ASPECTS
10), but interpreted the CTA-SI as showing at least some ischaemic change
(ASPECTS<10). There was no evidence of reversibility of CTA-SI seen in this
study. Figure 5 shows a scatter plot ofmean ASPECTS scores for CTA-SI and
NCCT as compared to final ASPECTS scores on follow-up imaging.
The rate of favorable outcome for NCCT ASPECTS of 8-10 was 51.8% versus
25.0% for 0-7 (RR = 2.1, 95% CI: 0.7 to 5.9, p-value=0.12). For CTA-SI ASPECTS
of 8-10, the rate of favorable outcome was 58.8% versus 31.8% for 0-7 (RR = 1.8,
95% CI: 0.9 to 3.8, p-value = 0.09). The inter-rater agreement for baseline ASPECTS
using NCCT was 0.71 versus 0.73 for CTA-SI.
4.3. Discussion
Acute ischaemic stroke requires urgent assessment of the clinical and
radiological features of the brain insult. The ability to identify an acute infarct on CT
is helpful in confirming the diagnosis of acute stroke63. A completely normal non-
contrast CT scan, seems ideal in terms of potential benefit (since no damage is
currently seen) from any possible therapies, but may introduce diagnostic uncertainty
for the stroke neurologist. Normal scans early into acute stroke are reasonably
common. The ECASS II experienced reviewers did not detect early ischaemic
changes in about 1/3 of infarcts that later appeared on follow-up CT114 and the
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NINDS investigators reported that only 31% of patients in the NINDS tPA trial had
evidence of early ischaemic changes.115 Our results suggest that CTA-SI ASPECTS
has a greater sensitivity to ischaemic changes and more accurately identifies the
volume of tissue that will ultimately infarct compared to NCCT alone. The cases
where one rater scored the scan as 10 show the potential advantage of using CTA-SI.
In 7 of these cases the ischaemia would have been totally missed by one of the expert
raters. It is in this setting (ASPECTS = 10 of the NCCT) where CTA-SI is most
likely to be helpful. However one could also argue that this would not make a
difference since most physicians would not withhold thrombolytic therapy on the
basis of a normal scan. In situations where the clinical diagnosis is unclear however
the CTA-SI may be potentially very helpful.
CTA is one method of quickly and accurately identifying vessel occlusion
and ischaemia. Using a follow up ASPECTS as the final infarct size, CTA-SI gives a
more accurate estimate of tissue that is at risk of infarcting than does a NCCT alone.
The value of a combined CTA, CTA-SI over NCCT in predicting clinical outcome
has also been demonstrated using a scale that differs from ASPECTS.116
It is important to recognize that hypoattentuation on NCCT and CTA-SI
hypoattenuation probably imply different pathophysiologic abnormalities. These
may not always represent core of infarction. A CTA-SI region showing a lack of
enhancement provides an estimate of CBV76'77 while NCCT measures shifts in brain
tissue water content. It is the net uptake of water in brain regions with hypoperfusion
less than 12 ml/100 g x min117'118 that causes hypoattenuation. Large shifts ofwater
are needed for the human eye to visualize hypoattenuation. Animal studies have
shown that a 1% increase in brain water content results in an x-ray attenuation
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decrease of 2-3 HU119. Optimal window width and leveling110 can help to identify
reliably such changes in water content. Recent work confirms that the volume of
abnormality on CTA-SI at baseline is a very close match to the volume of final
infarct on follow up scanning if there is prompt recanalization77. Further work is
needed on this subject.
Both NCCT and CTA-SI showed a trend towards a better clinical outcome
for baseline ASPECTS of 8-10. This is consistent with observations from the
PROACT-2 trial where an ASPECTS of 8-10 was found to differentially predict
response to thrombolytic treatment.56 Larger numbers of patients will be needed to
assess and confirm the relationship of ASPECTS on CTA-SI with clinical outcome.
The possibility of CT fogging effect is a relative limitation of our study.
The timing and degree of fogging is variable, and has mostly been studied in
small series, on older generation CT scanners.120'1 1 More recent papers suggest that
fogging can start as early as 5-10 days post ictus, but that it may also occur months
after stroke onset, coincident with the time period of post stroke hyperemia122 (a
potential mechanism of fogging). The timing and degree of fogging likely varies with
factors such as infarct size, as well as the severity of the initial deficit.123 Importantly
for our results, previous work suggests that fogging of large infarcts is typically not
complete.
Another potential limitation of this study is the fact that the CTA was always
performed after the NCCT. Previous studies using CTA in this protocol however has
shown that the CTA is only delayed by around 10 minutes as compared to the
NCCT. This is one potential reason for the increased ischaemia seen on the CTA-SI.
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The reliability of assessing ASPECTS on the CTA-SI was very good and
similar to that on non-contrast CT. Larger studies are needed very early from stroke
onset to compare both techniques. NCCT changes are particularly difficult to
appreciate in such patients and may be greatly aided by CTA-SI information. In
centres not used to examining NCCT for early ischaemic changes this technique may
aid in the identification of ischaemia.
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Figure 3: 75 year old man with left hemiplegia and hemineglect syndrome
caused by a right MCA occlusion. Unenhanced CT scanning was performed
62 minutes after symptom onset; NIFISS was 15 at baseline. A. Possible
subtle right lentiform / subinsular ischaemic hypodensity; this scan received
an ASPECTS rating of 10 from one of the experts, and 9 from the other. B.
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Corresponding CTA-SI images, obtained immediately following the NCCT,
showed unequivocal hypocontrastation involving the caudate nucleus,
lentiform nucleus, M2 territory, and insula. Red arrows point out these areas.
This scan received an ASPECTS rating of 6 from one of the experts, and 2
from the other. C. Follow-up CT reveals progression to infarction in the
territory of the CTA-SI lesions, despite successful vessel recanalization
following IV and IA rt-PA. The raters scored the follow up scan as having
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Figure 4: A comparison of mean ASPECTS score at baseline between non-
contrast CT (NCCT) and CTA-source images (CTA-SI) according to three
categories of ASPECTS scores at follow-up. The 95% confidence intervals
about the mean score (vertical lines) and the p-values (along the horizontal
axis) were computed from a two-factor repeated measures analysis of
variance. The p-values correspond to comparing the mean scores (reported
above the p-values) between NCCT and CTA-SI for each category of follow-
up ASPECTS score. In general, the baseline ASPECTS score for CTA-SI
was lower than for NCCT and was closer to the midpoint of the category for
the follow-up ASPECTS score.
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Figure 5: Scatter plot of mean ASPECTS scores for CTA-SI and NCCT
compared to final ASPECTS scores on follow-up imaging. The estimated
lines are derived from simple linear regression equations and imply that there
is a consistent difference between NCCT ASPECTS and CTA-SI ASPECTS
regardless of final infarct volume.
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5. Chapter 5: Reliability of Assessing Percentage
Diffusion-Perfusion Mismatch
56
In acute stroke when the acute PWI lesion volume is larger than the DWI
lesion volume (referred to as mismatch) often the stroke evolves and grows.124'125'126
Tissue with hemodynamic change but without DWI ischaemic lesions may be
salvageable. Thus, mismatch has come to be used in patient selection for
thrombolysis.103 Visual estimation of the three-dimensional (3D) mismatch is
difficult. The aim of the present study was to examine the inter- and intra-rater
reliability of visually estimating the percentage mismatch. The study parameters
were chosen to mimic a clinical real-time assessment ofmismatch that would be used
to inform clinical decision making regarding thrombolysis.
5.1. Methods
5.1.1. Patients
The present study was part of an institutionally approved protocol of emergency MR
imaging of acute stroke patients performed from October 1999 to February 2002.
Thirteen patients were selected retrospectively from the acute stroke MR database.
An investigator who was not a rater selected study subjects randomly from the
database. All patients were scanned within seven hours of symptom onset, showed
evidence of diffusion- (with restricted apparent diffusion coefficient (ADC)) or
perfusion-weighted MRI changes, and had optimal scan quality. Patients were
chosen to reflect a variety of diffusion and, perfusion lesion sizes, location of infarct
and clinical characteristics. The scans included examples of large, medium and small




MR images of the brain were obtained using a 3-Tesla scanner (Signa; GE
Medical Systems, Waukesha, WI) equipped with high performance gradients (40
mT/m, 184-ps rise time). All imaging was performed using a standard quadrature
head coil. The acute stroke imaging protocol included standard anatomic imaging
(T2-weighted, FLAIR and magnetic resonance angiography), DWI and PWI. Only
the latter two imaging sequences were evaluated in this study. DWI was performed
with a single-shot spin-echo echo-planar imaging technique with a diffusion
sensitivity of b= 1000 s/mm2, 7000 ms/96 ms (TR/TE), 19 5-mm slices with 2-mm
gap, 32 x 19-cm field-of-view (FOV) and a 192 x 192 acquisition matrix
reconstructed to a 256 x 256 matrix. PWI used a single-shot gradient-echo echo-
planar sequence with 2200 ms/25 ms. Ten 6-mm sections with a 3-mm gap, 32 x 19-
cm FOV, and a 192 x 192 acquisition matrix were reconstructed to a 256 x 256
matrix. Five hundred and ten images were collected over 112 s during the
intravenous administration of a 20-mL bolus of gadopentetate dimeglumine
(Magnevist; Berlex, Wayne, NJ) injected at 5 mL/s. PWI acquisitions on our scanner
were limited to collection of a maximum of 512 images. In this study, we chose to
collect 51 time-points over 112 s (which necessitated a TR of 2200 ms) and to collect
10 slices at each time point. This long TR was chosen due to the fact that in acute
stroke the blood flow is often slow and we need to acquire perfusion maps over the
90 to 120 s range. In order to increase the PWI coverage, the slice thickness and gap
were increased compared to the DWI acquisition.
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5.1.3. Image analysis
The MR scans were independently assessed twice by six raters (two
neuroradiologists, two stroke neurologists and two stroke fellows), blinded to all
clinical information. All raters were experienced in assessing the acute changes of
stroke on MR imaging. The DWI images were examined for evidence of restricted
diffusion on a clinical workstation (Advantage Windows, General Electric Medical
Systems). Mean transit time maps (rMTT) were created using manufacturer-supplied
software (Functool 2000, General Electric Medical Systems). Each rater was trained
and used the same method. A PWI abnormality was considered present if there was
any visible abnormality on the rMTT map when viewed on a grey scale. The DWI
and PWI images were viewed on the MR workstation simultaneously. Windowing
was adjusted by the rater, with no fixed levels designated. If DWI>PWI then the scan
was rated as having reverse mismatch. IfPWI=DWI then a matched deficit was
considered present. If there was no evidence of a DWI lesion, but there was a PWI
lesion, then mismatch = 100%. If PWI>DWI then the percentage mismatch between
DWI and the rMTT map was estimated [((rMTT volume-DWI voIume)/rMTT
volume)* 100%] to the nearest 10%. This lead to an estimate of the three dimensional
mismatch in lesion volumes. The raters repeated the above procedures after a period
of at least two weeks, to determine intra-rater reliability.
Four raters manually drew lesion outlines around the DWI and rMTT lesion
areas on all images twice, separated by a period of at least one week between each
rating. Displayed image contrast (window and level settings) was allowed to be
varied to optimize visualization of the lesions. Lesion volumes were calculated for
each image and the percentage mismatch calculated where volume = [area x slice
number x (slice thickness + interslice gap)].
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Estimates of inter-rater and intra-rater reliability and standard error of
measurement (SEM) were calculated simultaneously from a two-way random effects
analysis of variance.127 One-sided, lower-limit 95% confidence intervals (CI) were
calculated about the estimates. Further analysis of reliability using dichotomized cut
off points at 10% and 20% mismatch was conducted. Suggested benchmarks for
reliability are as follows: Slight 0.00-0.20, Fair 0.21-0.40, Moderate 0.41-0.60,
Substantial 0.61-0.80, Almost Perfect 0.81-1.001".
5.2. Results
The sample of patients included six women and seven men. The median age was
65 years (range 45-82 years), median time from symptom onset to scan was 152
minutes (range 72-420 minutes), and the median NIHSS was 5 (range 0-18). An
example of a MR scan used in the present study is shown in Figure 6.
For visual assessment representing the state-of-the-art for real-time clinical
decision making, the inter-rater reliability among six raters was 0.68 (95% CI: 0.52
to 1.0; SEM=21.6%). The intra-rater reliability was 0.80 (95% CI: 0.47 to 1.0;
SEM=16.9%). Using a dichotomised cut-off point of >10% versus <10% mismatch,
the inter-rater reliability was 0.71 and intra-rater reliability of 0.78. A dichotomized
cut-off point of >20% versus < 20% mismatch had lower reliability (inter-rater=0.60,
intra-rater=0.72). For PWI-DWI mismatch derived from volume calculations based
upon lesion tracing, the inter-rater reliability among four raters was 0.66 (95% CI:




Results from the present study suggest that quantifying mismatch by the
human eye is reproducible, but not reliable among observers. The margin of error
between raters was large. For example if one rater was to estimate the percentage
mismatch as 10% and another were to estimate it at 40%, then the difference of 30%
would still be within the error of the measurement (+/- 21.6%).
The prognostic significance of mismatch where the PWI lesion is defined by
the rMTT remains unclear, but this method has made its way into clinical decision
making and trial design. For example the Desmoteplase in Acute Stroke (DIAS)
trial102, tests the hypothesis that patients with 20% or greater DWI-PWI mismatch
will benefit from use of intravenous desmoteplase in a 3-to 9-hour time window. We
conclude from the results of the present study that real-time determination of
percentage mismatch may lead to inaccurate clinical characterization for the
individual patient. Additionally the failure to account for this error may lead to
underpowered clinical trials. However, the level of intra-rater reliability may be
sufficient for central review of images by a single individual.
This study was performed at 3.0 T. Imaging at this field strength had a
number of advantages and disadvantages compared to 1.5 T. Within the context of
this study, 3.0 T imaging would intrinsically have had a higher signal to noise ratio,
which was used to acquire higher than typical resolution DWI and PWI data. DWI
contrast is independent of field strength, whereas PWI contrast in T2*-weighted
imaging increases with field strength. In this study the echo time at 3 T (25 ms) was
reduced to compensate for the additional T2*-weighting.
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Advances leading to rapid creation of quantified perfusion maps and
computer-assisted volume measurements128 may obviate the need for visual estimates
of mismatch in the future. In the interim we would caution the use of visual
inspection of mismatch as the deciding factor in treatment or trial enrolment.
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Figure 6: Top row shows DWI changes in the right MCA territory. Second row
show the rMTT map for this case, with PWI>DWI lesion (mismatch). This
case was rated by the six experienced observers as having a mismatch
ranging from 30 % to 100 %. The error range of the measurement across all
cases is ± 21.6%.
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6. Chapter 6: Presence of DWI lesion on acute MRI in
minor stroke and TIA patients predicts recurrent stroke
and clinical outcome.
Brain imaging may offer the opportunity to better risk stratify those presenting to
the emergency room with a non-disabling ischaemic cerebrovascular event. We
hypothesized that among patients presenting with a TIA or minor stroke, the
presence of a DWI lesion would be predictive of both the future occurrence of stroke
and disability at 3 months. Secondary aims of this study were to determine whether
either the classical definitions or new proposed definitions of stroke or TIA were
predictive of future stroke or disability33'39.
6.1. METHODS
6.1.1. Patients
We prospectively enrolled consecutive patients presenting to a single
academic institution with symptoms of minor stroke or TIA, consisting of
hemiparesis or aphasia lasting more than five minutes who were examined by a
stroke neurologist within 12 hours of last seen well. Additional inclusion criteria to
be met were: NIHSS < 3, older than 18 years of age, and functionally independent on
the modified Rankin scale (< 2) at baseline. The research protocol was approved by
our institutional ethics committee and all participants provided written informed
consent. Patient demographics and clinical history were recorded at the time of
admission to the emergency department. All patients were examined by a stroke
neurologist. TIA was defined according to the World Health Organization criteria129
as rapidly developed clinical signs of focal or global disturbance lasting fewer than
24 hours, with no apparent nonvascular cause. At 24 hours ± 8 hours, post-
symptoms, a stroke neurologist confirmed the diagnosis of TIA if all symptoms had
65
resolved. The time to symptom resolution was recorded. If the patient's symptoms
had not resolved by the time of going to sleep, but had resolved the next morning, the
time to resolution was recorded as the time of awakening.
6.1.2. Imaging
MR imaging was performed as soon as possible after arrival in the emergency
department and within 24 hours of symptom onset. Images were obtained using a 3-
Tesla scanner (Signa; GE Medical Systems, Waukesha, WI) equipped with high
performance gradients (40mT/m, 184-ps rise time), using a standard quadrature head
coil. Sequences included sagittal Tl, axial T2, axial FLAIR, DWI (B=1000), and 3D
time-of-flight MR angiography (MRA) of the intracranial circulation.130 Imaging
was assessed by a neuroradiologist blind to all clinical information other than
symptom side and any subsequent imaging information if applicable. The four MR
sequences DWI, ADC, FLAIR and T2 were examined for presence of a new acute
stroke lesion (Figure 7). The MRA was assessed using source images and maximum
intensity projection reformats for evidence of vessel occlusion.
6.1.3. Patient outcomes
Patients had a neurological assessment at 24 hours, 1 month and at 3 months
after their presenting event to the emergency department. The National Institutes of
Health Stroke Scale (NIHSS)106, modified Rankin scale131'132 and the Questionnaire
to validate stroke-free status (QVSFS)109 were completed by the neurologist at 1 and
3 months. Occurrence of stroke during follow-up was defined as a functional
deterioration in neurological status of vascular origin or a new sudden focal
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neurological deficit of vascular origin lasting more than 24 hours. If a patient had a
stroke or TIA during follow-up, their brain imaging and clinical records were
reviewed by a stroke neurologist to confirm the diagnosis. At 3 months, after
reviewing all clinical and imaging information, the final diagnosis of the presenting
event was made and the potential mechanism assigned using the TOAST133
classification.
6.1.4. Statistical Analysis
The primary outcome was new stroke occurring within 90 days of the
presenting event. Patients had varying lengths of follow-up as some died and others
had carotid endarterectomy during the 90-day follow-up period, at which point the
data were censored. The crude (unadjusted) risk of stroke was estimated from
Kaplan-Meier event-free survival analyses. Stratified Cox proportional hazards
regression modeling was used to adjust for differences in patient characteristics
among the groups. Adjusted stroke-free survival curves were plotted using product-
limit estimates. Differences among the curves were assessed for statistical
significance using a likelihood ratio test. Logistic regression analysis was used to
adjust the frequency distribution of 90-day Rankin scale scores for differences in pre¬
morbid Rankin scale scores. Differences among proportions in patient characteristics
were assessed for statistical significance using a chi-square test.
6.2. Results
A total of 120 patients were enrolled in this study between May 2002 and
May 2004, including 69 (57.5%) TIAs. Five patients had a diagnosis other than
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stroke or TIA after review of all information at 3 months. The mean age of the 120
patients was 66.0 years and 75 (62.5%) were male. Among these, 15 patients
(12.5%) had a DWI lesion and vessel occlusion on the baseline MR scan (7 middle
cerebral artery, 5 internal carotid artery, 1 anterior cerebral artery, and 2 posterior
cerebral artery). Of the remaining patients, 54 (45.0%) only had a DWI lesion and 51
(42.5%) had neither. Baseline characteristics are shown in Table 1. The mean time
from symptom onset to MR imaging was not significantly different among the
groups. Patients with a DWI lesion were significantly more likely to have a TOAST
classification of large-artery disease compared to patients without a DWI lesion,
especially in the presence of vessel occlusion.
A total of 14 patients had a stroke within 90 days, of which 9 (64.3%)
occurred within the first 48 hours. Patients with a DWI lesion were at a higher risk
of a stroke during follow-up than patients without a lesion, and highest in the
presence of vessel occlusion. The unadjusted Kaplan-Meier 90-day risks were 4.0%,
11.6%, and 40.7%, respectively (logrank p-value < 0.001). Baseline NIHSS score
and blood glucose > 7 mmol/L were the only patient characteristics identified to be
confounding factors from Table 1. Patients with a NIHSS score of 1, 2, or 3 were 1.7
times more likely to have a stroke than patients with a score of 0 (95% CI: 0.4 to 6.8,
p-value = 0.42). Patients with an elevated glucose level were also 1.7 times more
likely to have a stroke (95% CI: 0.6 to 5.2, p-value 0.36). Even after adjustment for
NIHSS score and elevated glucose in a Cox regression, patients with a DWI lesion
remained at increased risk (Figure 8). In comparison to patients without a DWI
lesion, patients with a lesion were 2.6 times more likely to have a stroke (95% CI:
0.5 to 13.1, p-value = 0.26), whereas those with a lesion and an occlusion were 8.9
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times more likely to have a stroke (95% CI: 1.6 to 49.6, p-value = 0.01). Statistically
significant differences among groups (p-value = 0.04) was also observed in terms of
90-day functional dependence and death (Rankin score >3). The highest proportion
was observed in patients with a DWI lesion and vessel occlusion (Figure 9). Only
one patient died during the 90-day follow-up period, and they were in the group with
a DWI lesion and no vessel occlusion. Patients with large-artery ischemia were no
more likely to have a stroke than those without large-artery ischemia (relative risk =
1.7 times, 95% CI: 0.5 to 5.3, P= 0.39).
Of the 69 patients with DWI lesion, 39 (56.5%) presented with a stroke,
compared with 13.7% of 51 patients without a DWI lesion. Therefore, the presence
of a DWI lesion was related to whether or not the patient had residual signs at 24
hours (P < 0.001). A total of 12 of the 46 (26.1%) patients with a presenting stroke
had a stroke at 90 days compared to 2 of 69 (2.9%) patients who presented with a
TIA (p< 0.001)
6.3. CONCLUSIONS
This study prospectively examined the predictive value ofDWI lesions in
patients presenting acutely with non-disabling cerebral ischaemic events (TIA or
minor stroke). Patients with a DWI lesion were at a higher risk of a stroke during
follow-up than patients without a lesion, and this was highest in the presence of
vessel occlusion. This was clinically significant since functional dependence was
predicted by the presence of a DWI lesion and vessel occlusion.
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Similar to others ' ' we found that that the high-risk period is within the
first 48 hours after the initial event, with 64.3% of events occurring during this
period. However, we enriched our population because our inclusion criteria utilized
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some of the important clinical features associated with increased risk of new stroke
(motor or speech deficits). Similar to others we found that an elevated blood sugar
confers a higher risk of recurrent events13. However, we did not find large artery
disease37 to be predictive of risk, although large artery disease is in the causal chain
since it was highly predictive of a DWI positive patient.
Our results show that the longer symptoms are present, the more likely a
patient is to have a recurrent event. However waiting for symptoms to resolve is not
practical particularly as the clinical diagnosis of TIA versus stroke is inaccurate134
even by neurologists. With most of the new strokes occurring within the first 48
hours waiting to see if all the symptoms resolve at 24 hours is not practical since
interventions will likely need to be instituted promptly. Admitting all TIAs is
prohibitively expensive,135 therefore some means of discriminating patients at high
immediate risk at the time they are seen is desirable. A recent proposal suggested a
redefinition of TIA as a brief episode of neurologic dysfunction presumptively
caused by focal brain or retinal ischaemia without neuroimaging evidence of acute
infarction.39 Our study provides further evidence to suggest that clinical TIA
syndromes can be differentiated by acute neuroimaging, rather than by an arbitrary
time definition.136 Others137 have also found that DWI lesions can predict further
vascular events. However this study was performed late with the majority of patients
being imaged later than 48 hours after their event. With approximately 50%13 of
recurrent events occurring in the first 48 hours after symptoms any imaging
abnormalities seen in these patients may actually be from recurrent events.
There has been previous work examining the role of both CT and MRI as
imaging strategies in this patient group. Recent work with computed tomography
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(CT) brain scans has shown that evidence of a new infarct on brain CT done within
48 hours of onset in TIA patients is associated with an increased short-term risk for
stroke, but did not relate this to functional outcome.138 Furthermore, brain CT is
insensitive to small volumes of injury and the proportion of new infarcts seen on CT
among TIA patients is substantially less than that seen on DWI.139'140 The use of
DWI has drawn attention to the high rate of new silent infarcts in stroke patients.141
However, no study has examined a reliable imaging finding (DWI lesion) in non-
disabling cerebral ischaemic events.
The group with the highest rate of new strokes was that with evidence of a
vessel occlusion and a DWI lesion. A high proportion (26.7%) of these patients are
dependent at 3 month follow up. This appears to be a high risk population and
potentially is a target for future therapeutic interventions. It must be emphasized that
although a significant minority do poorly, nearly three quarters do well implying that
any therapies must have minimal risk of adverse effects.
TIA or minor stroke patients without DWI lesions represent a group with a
more benign prognosis. A proportion of these patients may have had a non-
ischaemic event of epileptic, migrainous or somatoform origin. These patients were
all seen by stroke neurologists who felt the diagnosis was vascular in origin. In our
study in only 5 patients did the diagnosis change on review of all the available
information at 3 months. The sensitivity and specificity of DWI for acute ischaemic
stroke is estimated to be 90%142,143,144 but caution is needed in assuming that a DWI
negative study completely rules out ischaemia. Slice thickness, in plane spatial
resolution, artifact from bone, air and CSF may reduce the conspicuity of or mask the
appearance of a stroke lesion. There is evidence supporting the notion that a small
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subset of patients with clinical strokes are DWI negative,145 particularly involving
the brainstem.146 The sensitivity and specificity ofDWI for acute ischaemic stroke is
estimated to be 90%.
This study has limitations. All imaging was performed using the increased
magnetic field strength of 3 Tesla. This may enhance detection of ischaemia using
DWI sequences by an improved signal to noise ratio147. Similar improvements in
DWI lesion detection can be achieved with more commonly available 1.5 Tesla
strength using sequences with higher resolution and higher signal to noise ratios 40
Our definition of new stroke was designed to identify a functional deterioration.
Clearly both an evolution of the original event causing progression of symptoms (for
example, lacunar disease) and a new lesion (for example re-embolization from heart
or large artery) would be included in such a definition. Clinical progression is often
difficult to differentiate from recurrence. Ideally a follow up MRI using strict
definitions for either process could differentiate the two. We did not mandate a
follow up MRI, but observe that from a patients perspective all that matters is a
deterioration in functional status.
In summary, the presence of a DWI lesion on an MRI in patients presenting
acutely with a non disabling deficit is indicative of an increased risk of new stroke
within 90 days. The risk is even greater in the presence of a vessel occlusion as well.
The presence of a DWI lesion is also predictive of subsequent functional
dependence. Acute MRI is useful in making a triage decision for patients with TIA
or minor stroke. This needs further validation in independent cohorts.
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Figure 7: A shows an example of a patient with a DWI negative scan. B
shows an example of a patient with a DWI positive scan. The white arrow






(N = 51) (N = 54) (N = 15)
P-value
Age > 60 years*
Male sex
Taking antiplatelet medication
Blood glucose > 7 mmol/L










Premorbid mRS 1 or 2 (not 0)
NIHSS score 1, 2, or 3 (not 0)




































































TIA = transient ischaemic attack; NIHSS = NIH stroke scale; MR = magnetic
resonance, mRS = modified Rankin Scale.
* Mean (SD) age of patients: 65.2 (14.5), 66.1 (14.3), and 68.1 (12.4) years,
respectively.
* Mean (SD) time interval from symptoms to MR: 10.6 (6.7), 9.4 (5.2), and 7.7 (5.0)
hours, respectively.
Table 1. Characteristics of Patients According to Presence and Absence of


























0.0 -1 1 T"
No DWI Lesion & No Occlusion 4.3%
Yes DWI Lesion & No Occlusion 10.8%
Yes DWI Lesion & Yes Occlusion 32.6%
Likelihood ratio test p-value = 0.02
~i r~
30 60 90
Days after Presenting Acute TIA or Minor Stroke
Figure 8: Stroke-free survival curves for patients with and without DWI lesion
and total occlusion, adjusted for NIHSS score and baseline glucose level.
The adjusted risks of stroke at 90 days are shown as percentages on the
right-hand side above the curves.
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Rankin Scale Score
□ 0-2 Q 3-6
No DWI & No Occlusion 98.1
Yes DWI & No Occlusion 93.8 6.2
Yes DWI & Yes Occlusion 79.0 21.0
Percentage of Group
Figure 9: 90-Day Modified Rankin scale scores of Patients enrolled with or
without DWI Lesion and total occlusion present on Baseline MRI, adjusted for
pre-morbid Rankin scores.
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7. Chapter 7: Mild neurological symptoms despite
middle cerebral artery occlusion
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Recent work suggests that absent middle cerebral artery (MCA) flow signal on
MRI correlates with poor clinical outcome148. We assessed whether the presence of
MCA flow abnormalities among mild stroke patients identified a subset of patients
that might deteriorate and be suitable for reperfusion strategies.
7.1. Subjects and Methods
Sequential patients with symptoms of an acute stroke were prospectively
included if they had both a CT scan competed in under 6 hours and a MR scan within
7 hours of onset. Exclusion criteria were the presence of cerebral hemorrhage, pre¬
existing significant non-ischaemic neurological deficits or non-stroke diagnosis.
Demographic data, stroke risk factors, and baseline National Institutes of Health
Stroke Scale (NIHSS) were recorded prospectively by a stroke neurologist or trained
stroke nurse. Mild neurological symptoms were defined as a NIHSS score of three or
less. The outcome measures were defined by the Rankin scale at three months,
categorized into independence (0 to 2), dependence (3 to 5), and death. We identified
patients with transient or minor neurological deficits (an NIHSS < three) and
evidence of a MCA occlusion on 3D time-of-flight MR angiography (MRA) at
baseline.
MR images, obtained using a 3-Tesla scanner (Signa; GE Medical Systems,
Waukesha, WI) equipped with high performance gradients (40mT/m, 184-ps rise
time), and using a standard quadrature head coil, included sagittal Tl, axial T2, axial
FLAIR, DWI, perfusion weighted (PWI) and 3D time-of-flight MR angiography
(MRA) and 3D time-of-flight MR angiography (MRA) post gadolinium.130 One
stroke neurologist experienced at interpreting MRA, blinded to all clinical
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information except symptom side, assessed the MRA in the anterior circulation for
areas of reduced or absent flow signal in the distal internal carotid artery (ICA) and
MCA. The MRA flow signal abnormality was categorized as: none, involving distal
ICA, Ml-MCA, M2-MCA or distal MCA.
One stroke neurologist retrospectively analyzed the images blind to clinical
details and outcomes, looking for evidence of DWI/PWI mismatch, defined as
present if the estimated volume of a PWI-abnormality was greater than the DWI-
abnormality volume. Matching DWI and PWI images were placed on the MR
workstation simultaneously. Functool (Functool 2000 User Guide, General Electric
Medical Systems) was used to create the perfusion maps. A PWI abnormality was
present if there was any visible abnormality on the relative mean transit time map
when viewed on grey scale.
Data are reported in frequency tables. Proportions were compared using
Fisher's exact test, continuous variables with a Student's t-test and ordinal variables
with a Mann-Whitney-U test as appropriate. All tests were two-sided and
conventional levels of statistical significance at 5% were used.
7.2. Results
A total of 106 consecutive patients were included between October 1999 to
July 2001. MR was commenced within the three hours of onset in 42% of patients
and 79% of patients underwent CT scanning within three hours of symptom onset.
An MRA was completed in 104 patients and 49 of these had evidence of flow
abnormalities. Five patients were identified with both a NIHSS score of three or less
(NIHSS<3) and isolated flow abnormalities seen on MRA in the MCA (two Ml-
MCA, three M2-MCA; see Figure 10 for an example) consistent with vessel
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occlusion. None of these five patients had symptoms suggestive of a lacunar
syndrome. Four of the five patients had evidence of DWI changes on MR. Of the
other 101 patients, 28 had NIHSS>3 and flow abnormalities on MRA in the MCA
without coincident ICA occlusion. All of the 28 patients with MCA occlusion and
NIHSS>3 had evidence of a DWI lesion at baseline. These two groups of patients
(MCA occlusion + NIHSS>3 and MCA occlusion + NIHSS <3) were analyzed
separately (Table 2). There was no statistical difference in the proportion of patients
who had CT or MRI within three hours of symptom onset, nor in the hemisphere of
stroke between the NIHSS <3 with MCA occlusion group (n=5), and the NIHSS>3
with MCA occlusion group (n=28).
All five patients in the NIHSS < 3 and MCA occlusion group were right hand
dominant and none of them of received thrombolytic therapy. One patient
deteriorated by two points on the NIHSS score in the first 24 hours, but all five were
independent on the modified Rankin Score at three months. See Table 3. All patients
with NIHSS<3 and MCA occlusion had a 30-day NIHSS that was less than or equal
to their admission score. In contrast, among patients with NIHSS> 3 and MCA
occlusion, 54% were dead or dependent at ninety days (p=0.09).
Two patients had a repeat MRA at 24 hours and both had evidence of
persistent occlusion. Five NIHSS <3 with MCA occlusion patients had perfusion-
weighted imaging performed on the acute MR scan and 2 patients had evidence of a
mismatch between DWI and PWI. There was no statistical difference between
presence of mismatch in the NIHSS <3 with MCA occlusion patients (n=5); and the
NIHSS>3 and MCA occlusion patients (n=24).
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7.3. Discussion
Persistent ischaemia in the absence of a severe neurological deficit has been
previously suggested using delayed SPECT.149 It is important to note that one patient
(20%) fluctuated neurologically, but all five were independent at follow-up. These
patients were all seen by the acute stroke team, considered for thrombolytic therapy
and not treated because of mild symptoms. The good prognosis in our study is
important because MCA occlusion and good prognosis have not been previously
associated. However, we advise caution at over interpretation of these results on the
basis of this small sample. All patients had evidence of a stroke on imaging in the
appropriate vascular territory that the vessel occlusion was seen. However we can not
rule out the possibility that some of these occlusions were chronic. If this were the
case it may bias our results towards good outcome.
With the increasing availability of non-invasive imaging, we routinely have
information about the site of vascular occlusion but do not have empiric evidence to
guide translation of that information into effective clinical decisions. Most physicians
would not offer thrombolysis to patients with mild stroke symptoms due to their
expected good prognosis, but in the NINDS tPA stroke study7 there were patients
with as low a NIHSS as 1 included. Although we know that "mild" patients can
deteriorate12 our experience suggests that despite vascular occlusion, these patients
may not be the population of stroke patients that deteriorate and need thrombolytic
therapy.
Vascular occlusion plays a major role in the prognosis of acute ischaemic
stroke, but the effect is likely mitigated by compensatory collateral blood flow. None
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of our patients recanalized within 24 hours suggesting that collateral flow remains
important for hours to days. The experience documented in the EC-IC bypass study
emphasizes this concept150. Reduced collateral blood flow assessed on CTA76 has
previously been shown to identify those at risk for infarct expansion. In the setting of
MCA occlusion with mild symptoms, good control of blood pressure with fluid
replacement or even induced hypertension may be beneficial151 by improving
collateral flow. A clinically useful tool to measure collateral blood flow might allow
stratification of patients with vascular occlusion into those who require reperfusion
and those who do not.
PET studies in primates and humans support the concept of perfusion
thresholds that predict early, late or no subsequent infarction152. Analogous
information is beginning to emerge using multimodal stroke MRI,153 but perfusion
MR currently only provides semi-quantitative data. Mismatch between PWI and
DWI has been proposed as a tool that identifies patients who are at risk of
deterioration and have potentially salvageable brain tissue.24 Post-hoc analysis
suggests that patients with PWI-DWI mismatch do not uniformly do badly101.
Absolute quantification of blood flow using MR may be crucial to predict patient
outcome by allowing the clinician to visualize tissue at risk of infarction.
Further study using neuroimaging is needed to understand mechanisms for clinical
deterioration and recurrent stroke in the mild stroke and TIA population39. We
suggest caution in recommending thrombolysis to patients with a mild symptoms and
MCA occlusion.
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NIHSS<3 + MCA NIHSS>3 + MCA
occlusion (n=5) occlusion (n=28)
Mean Age 64.3 65.5
Median NIHSS 3 16
tPA - iv or ia 0 15
Number of males 4 20
Left side of body event 3 10
Mean Initial blood 8.3 6.8
glucose
Mismatch on MR 2 6 (n=24)
M1-MCA occlusions 2 16
M2-MA occlusions 3 12
Table 2: Demographic characteristics of NIHSS < 3 + MCA occlusion group
compared to the group of patients with NIHSS>3 + MCA occlusions. None of
the comparisons were statistically significant.
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NIHSS 24hr 30 Day Hemi¬ 3 month Site of Follow-up
baseline NIHSS NIHSS sphere modified Vessel MRA
Rankin occlusion
1 3 1 0 Right Independent M2 No recan-
alization
2 2 0 0 Right Independent M2 utd
3 2 4 1 Left Independent Ml utd
4 3 3 2 Right Independent Ml No recan-
alization
5 3 1 0 Left Independent M2 utd
Table 3: Breakdown of five patients with NIHSS<3 and MCA occlusion.
UTD = unable to determine.
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Figure 10: Case 4. 60 year old man who developed left sided weakness and
dysarthria. He improved en-route to hospital and on arrival in the ER he had
a NIHSS of three. MRA showed attenuated flow (white arrow) at the MCA
bifurcation (A) with complete occlusion of the superior M2 division and
diminished flow in the inferior M2 division. His DWI imaging initially showed
no evidence of a lesion. (B). PWI showed a large area of Mean Transit Time
(MTT) delay (C). He had a fluctuating clinical course over the next 24-48
hours, with a NIHSS varying between three and six. He was treated with
volume therapy, did not deteriorate further and at 30 days had a follow up
scan. FLAIR (D) shows right insular infarction. He was functionally
independent and had a NIHSS of two.
86
8. Chapter 8: Silent Ischaemia in Minor Stroke and TIA
patients identified on MR imaging
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Many studies have shown a high incidence of recurrent events in minor
stroke and TIA patients.13 Recent work has shown that in a general population of
stroke patients admitted to one hospital the rate of new lesions seen on MRI at 1
week as compared to the baseline scan was much higher than expected.140 It was also
found that many of these events were clinically silent. The population studied
included patients that were treated with thrombolysis or had evidence of a perfusion
abnormality on their baseline MRI. We sought to determine if the same risk applied
to patients with TIA or minor stroke. Further, we explored predictors of new lesion
development on follow-up MRI.
8.1. Methods
8.1.1. Subjects
In a prospective study of TIA and stroke patients presenting to a tertiary
referral centre within 12 hours of symptom onset, we examined patients with an
NIHSS<6 at baseline who were imaged with a 3T MRI at baseline and at 30 days.
This cut off was used since at out institution most patients with a deficit at this level
would not normally be treated with tPA. Follow up imaging was reviewed for
evidence of any new ischaemic lesions distinct from the original infarct, as compared
to the baseline MR. Demographic data were collected including whether iv tPa was
given, glucose, BP, history of hypertension, atrial fibrillation, smoker, diabetes and
valvular heart disease. Any new clinical strokes were recorded and the date of the
event was also recorded. Patients were treated acutely with tPa if the treating
physician wished to do so and secondary prevention with anti-platelet agents was left
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at the discretion of the attending neurologist; however, routine treatment at our center
includes treatment of hypertension, use of antiplatelet therapy or anticoagulant
therapy, treatment of hyperlipidemia with statin agents and dietary and lifestyle
counseling.
8.1.2. Imaging
Images were obtained using a 3-Tesla scanner (Signa; GE Medical Systems,
Waukesha, WI) equipped with high performance gradients (40mT/m, 184-ps rise
time), using a standard quadrature head coil. Acute imaging sequences included DWI
(isotropic b = 0 and 1000 s/mm2, TR = 7000 ms, TE = 96.5 ms), PW1 (TR = 2250,
1750 and 1850 ms; TE = 40, 45 and 45 ms; flip angle = 45°; 26, 51 and 42
repetitions), sagittal Tl, axial T2, axial FLAIR, 3D time-of-flight MR angiography
(MRA) of the intracranial circulation and ADC maps were calculated from the DWI
with the General Electric workstation.130 The changes in the PWI were due to
sequence optimization and corresponded to the acquisition of 19, 10 and 12 slices,
respectively. All images were acquired with a 320 mm field of view with 5.0 mm
slice thickness and 2.0 mm gap. The images were reconstructed to dimensions of 256
x 256 voxels. Mean transit time (MTT) maps were calculated from the concentration-
time curves obtained from the PWI series.
Imaging was assessed by a neuroradiologist blind to all clinical information
other than symptom side and any subsequent imaging information if applicable. The
MR sequences were examined for the presence of an acute stroke lesion on the
baseline MRI. If there was a lesion present this was further classified into whether
there was a solitary lesion or multiple. The MTT map was examined for any delays
in perfusion. Any delay in mean transit time as compared to the opposite side was
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considered abnormal. The MRA and post gadolinium MRA; source images and
MIP's were examined for evidence of any flow voids consistent with vessel
occlusion. The 30 day follow up MRI was rated with the acute MRI scan visible
simultaneously. Any new lesion outside the original DWI lesion was rated as being a
new lesion. The simple expansion of the baseline DWI lesion was not regarded as
being a new lesion. In some cases this was difficult to assess and therefore a
consensus was reached between 3 raters (1 neuroradiologist and 2 stroke
Neurologists). New lesions were further stratified into; 1 .new lesion within the
baseline perfusion abnormality; and 2. new lesion outside the original perfusion
abnormality.
8.1.3. Clinical follow up
Patients were examined at the time of their 30day MRI scan blind to their
imaging results and the QVFVS109 was used to identify any recurrent events that had
not been known to the investigator previously. The patients were also reviewed at 3
months at which time their final clinical assessment was made. NIHSS, modified
Rankin Score and Barthel scales were all completed at 30days and at 3 months. At 3
months the TOAST133 classification was identified for each patient: 1. large artery
atherosclerosis; 2. Cardio-embolism; 3. Small vessel occlusion, 4. Stroke of other
determined cause and 5. stroke of undetermined cause. Each patients chart was
reviewed by 1 individual and every recurrent event and TOAST criteria was double
checked. Any patients in whom there were discrepancies between the clinical




The data are described using simple descriptive statistics. Proportions were
assessed using the Fisher's exact test or Chi square test as appropriate. A Chi square
test for trend was used to assess 2 x n contingency tables. Comparisons among
groups were made using one-way ANOVA or the Kruskal-Wallis test. Within
ANOVA, comparisons were adjusted using the Bonferonni method. Logistic
regression analysis was used to assess the association between presence of new
lesions on MRI and clinical and MR factors.
8.2. Results
The total number of patients meeting the entry criteria was 143 and these
were enrolled between May 2002 and February 2004. 65 patients were classified as
having had a TIA as per the classical definition,129 the median NIHSS was 2
(interquartile range (IQR) 0-3) and 56 patients were female (39.2%). 29 patients
(16.9% (29 out of a potential 172 patients who had a baseline MRI completed) were
excluded from the study due to the 30 day MR not being completed (reasons
included; lost to follow up, claustrophobia, cardiac valve inserted etc.). 7 patients
(4.9%) were treated with intravenous tPA. The median time to baseline MR scan was
8.5 hours (IQR 4.8-15.8 hours). The median time from symptom onset to follow up
MR was 29 days (IQR 26-32 days). 46 patients (32.1%) had no evidence of a DWI
lesion on their baseline MRI scan; 71 patients (49.7%) had evidence of a solitary
lesion on baseline MRI and 26 patients (18.2%) had multiple lesions on their MRI.
Table 4 shows the clinical characteristics for each group. Diabetes and large artery
disease were more likely in the group with multiple baseline lesions.
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14 patients (9.8% CI95 5.5-15.9) had MR evidence of recurrent lesions on
their MRI at 30days. 10 of these patients (71.4%) had new lesions outside the
original area of perfusion abnormality (as defined by the MTT map). Of these
recurrent lesions 6 were clinically asymptomatic (42.9%); 6 had new strokes (42.9%)
and in two patients (14.2%) symptoms appeared to be explained by progression in
the first 24 hours of their stroke (both these patients had recurrent lesions in the area
of original perfusion abnormality). In one TIA patient the baseline MR showed no
DWI abnormality, however the follow up scan showed a new DWI lesion that had
been clinically silent. Figures 11 and 12 show examples of patients' who had new
MR lesions seen on 30day follow up MRI.
In univariable analysis, elevated baseline glucose (OR 1.26 per mM increase
in baseline glucose, CI95 1.0-1.6, p=0.034) and diabetes (OR 3.2 CI95 0.97-10.6,
p=0.056) were associated with new lesions on MRI at 30 days. A trend to increased
likelihood of new lesions at 30 days was seen with progressing baseline scan lesion
number (none, solitary, multiple: p=0.046). The absolute increase in risk of a new
MRI stroke at 30 days was 11.2% (CI95 3.2-19.2, RR = 6.2) with any baseline DWI
lesion. When grouped together, patients with large artery disease or cardioembolic
causes of TIA or minor stroke were more likely to have recurrent events on MRI at
30 days compared to other stroke types (RR= 2.9 CI95 1.0-8.4, p=0.043). In a
multivariable model adjusting for age, baseline serum glucose and increasing lesion
number were associated with new MRI lesions at 30 days, but these results were not
statistically significant at p<0.05.
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8.3. Discussion
Recurrence of ischaemia as defined by MRI was reasonably frequent (9.8%)
in our sample despite the fact that the patients had only mild or no clinical deficits at
the time of enrolment. We found that almost half of these lesions were clinically
asymptomatic. The only factors in our study predictive of recurrent ischaemic lesions
were the number of baseline lesions and baseline serum glucose. This seems intuitive
in that if you have more lesions at baseline you are likely at higher risk for recurrent
lesions. In support of this, other groups have found that multiple lesions at baseline
on MRI predict recurrent clinical events.154
Our study differed from that by Kang et.al. 141 in that they found the rate of
any recurrent lesions to be 34%. One reason for this is that the populations of
patients are different; we examined only mild stroke and TIA patients (NIHSS<6). In
their study they looked at all patients in a general hospital and many of the patients
had severe strokes. However the approximately 10% risk of a recurrent ischaemic
lesion shows that minor stroke and TIA not only have a high risk of clinical
strokes,13 but also of accumulating silent ischaemia. Although the risk of recurrent
imaging ischaemia was less than in previous studies, the amount of silent ischaemia
was high at around 46%. Previous studies have suggested that the rates of clinical
recurrence after all types of stroke is between 3.3% to 6% in 30days155'156 and this is
consistent with our results. This is important since it suggests that despite best
medical secondary prevention these patients are still at risk of recurrent ischaemia.
Patients presenting with "mild" clinical events are at significant risk of on-going
cerebral ischaemic damage. Other than the risk of a clinical symptomatic stroke,
there appears to be other risks with the accumulation of silent ischaemia. This is one
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of the proposed mechanisms for cognitive decline in patients with high grade
asymptomatic carotid disease.157
There have been many publications on the high risk of recurrent clinical
II if "if in
events in TIA > • • ■ and minor stroke patients, however none of them have
looked at recurrent imaging events. New events on MR are more frequent than
clinical events and thus may be useful as a surrogate outcome for acute stroke
prevention trials. This is a strategy which has proved very successful in identifying
treatment response in multiple sclerosis.158'159 It may be possible in the future to
monitor a patients MRI scan for evidence of active disease since this appears to be
more sensitive than waiting for clinical recurrent disease. There is little evidence
currently to say definitively that recurrent MR lesions that are clinically silent are a
negative thing. However there is emerging evidence that clinically silent recurrent
infarcts on MRI are however associated with cognitive decline.160'161 Our study
found the only risk factor for recurrence of ischaemic lesions on MRI was multiple
lesions on the baseline MRI. Like others we showed that large artery disease and
cardioembolic mechanisms are associated with an increased risk.141'38
In conclusion minor stroke and TIA are associated with a 10% risk of
recurrent events based on imaging, however this is much lower than is seen in more
severely affected patients. Patients with multiple lesions at baseline are at an










Age (median, iqr) 73.5 (58-
78)
69.5 (60-76) 69.5 (59-76) 0.720
Female Gender 39% 43% 31% 0.583
NIHSS (median,
iqr)
0 (0-2) 2 (0-3) 2(1-3) 0.078*
Diabetes 7% 18% 31% 0.028**
Atrial fib 15% 4% 15% 0.070**
Hypertension 54% 61% 58% 0.788**
Current Smoker 13% 20% 31% 0.194**
Ischaemic heart dx 17% 15% 8% 0.573**
Glucose (mM) 6.2(1.3) 6.6 (2.2) 7.8 (2.1) 0.004f
MAP (mmHg) 108(17) 108(15) 113 (18) 0.3011
TOAST 0.0641
Large artery 8.7% 21.1% 34.6%
Cardioembolic 19.6% 18.3% 15.4%
Small vessel 13.0% 18.3% 7.7%
Other determined 0% 5.6% 0%
Undetermined 58.7% 36.6% 42.3%
* Cruskal-Wallis test.
**Fisher's exact test
tOneway anova. In post-hoc comparison between groups, glucose was higher in the
multiple DWI lesion group compared to both solitary DW1 lesion group (P=0.024)
and to no DWI lesion group (P=0.003) after Bonferonni adjustment.
JChi square test
Table 4: Comparison of the demographics of minor stroke patients
(NIHSS<6) depending on the presence of no DWI, single or multiple DWI
lesions.
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Figure 11: A, B, C and D show the baseline MRI of a 79 year old female with
a left ICA and M1 occlusion, with initially a small DWI lesion. She presented
with a baseline NIHSS of 2 consisting of mild right sided weakness and
progressed to severe right hemiparesis. 12 hours after admission to hospital.
The MTT map showed only a mild MTT abnormality, but it was larger than
the DWI lesion. E and F show the 30day DWI scan with a new DWI lesion in
the same vascular territory, but outside the original perfusion abnormality.
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Figure 12: A. Normal scan at baseline (no DWI lesion seen, no vessel
occlusion and no perfusion abnormality) in a 79 year old male patient with a
left hemispheric TIA lasting 90 minutes - B. The patient remained clinically
asymptomatic. B shows a small new DWI lesion in left MCA territory seen at
30days on follow up MR.
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9. Chapter 9: A high proportion of TIA patients show
perfusion abnormalities despite resolution of symptoms
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Many patients with TIA, according to this classical definition, have injury
observed on diffusion weighted imaging (DWI) of the brain.41'42'43'44'45 The
assumption that TIAs are associated with complete resolution of brain ischaemia
leaving no permanent brain injury39'40 is clearly not true. There is growing evidence
that TIA is not a benign condition and the substantial risk of a subsequent stroke after
a TIA urges prompt evaluation so preventative measures may be taken.3'4 13 The risk
of a disabling stroke is high within the first 48 hours after the initial event13
suggesting that TIA is an unstable condition. Persistent ischaemia in the absence of
symptoms is one potential mechanism for recurrent stroke after TIA. In this
prospective study we sought to see ifMRI perfusion abnormalities exist early in TIA
patients despite the rapid resolution of symptoms.
9.1. METHODS
We prospectively enrolled consecutive patients greater than 18 years old
presenting to Foothills Medical Centre with symptoms of a TIA consisting of
hemiparesis or aphasia (speech or motor deficits) examined within 12 hours of
symptom onset. Our institutional ethics committee approved the research protocol
and proper written informed consent was obtained. Demographic information and
clinical history was obtained at the time of the arrival to the emergency room. A
stroke neurologist examined all patients included in the study. TIA was clinically
defined using the World Health Organization (WHO) definition129, as rapidly
developed clinical signs of focal or global disturbance lasting fewer than 24 hours,
with no apparent nonvascular cause. TIA was confirmed by a stroke neurologist 24
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hours post symptoms if all symptoms had resolved. The amount of time until
symptom resolution was documented.
9.1.1. Imaging
MR imaging was performed as soon as possible after arrival in the emergency
department and within 24 hours of symptom onset. Images were obtained using a 3-
Tesla scanner (Signa; GE Medical Systems, Waukesha, WI) equipped with high
performance gradients (40mT/m, 184-p.s rise time), using a standard quadrature head
coil. Acute imaging sequences included DWI (isotropic b = 0 and 1000 s/mm2, TR =
7000 ms, TE = 96.5 ms), PWI (TR = 2250, 1750 and 1850 ms; TE = 40, 45 and 45
ms; flip angle = 45°; 26, 51 and 42 repetitions), sagittal Tl, axial T2, axial FLAIR,
3D time-of-flight MR angiography (MRA) of the intracranial circulation and ADC
maps were calculated from the DWI with the General Electric workstation130. The
changes in the PWI were due to sequence optimization and corresponded to the
acquisition of 19, 10 and 12 slices, respectively. All images were acquired with a 320
mm field of view with 5.0 mm slice thickness and 2.0 mm gap. The images were
reconstructed to dimensions of 256 x 256 voxels. Mean transit time (MTT) maps
were calculated from the concentration-time curves obtained from the PWI series.
9.1.2. Image interpretation
Imaging was assessed by a neuroradiologist blind to all clinical information
other than symptom side and any subsequent imaging information if applicable.
Images were all examined on 2 large 23inch monitors. Contrast was allowed to be
altered to emphasize differences between tissues. The images were examined for the
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presence of an acute DWI lesion; none, solitary and multiple. The MTT map was
examined for the presence of a perfusion delay and then the 2 series were examined
for the presence of mismatch (MTT abnormality>DWI lesion), matched deficits
(MTT=DWI) and reverse mismatch (DWI>MTT). The MRA of the circle of Willis -
pre and post Gadolinium; MIP's and source images were examined for evidence of a
flow void consistent with a vessel occlusion.
9.1.3. Patient Outcomes
Patients had a neurological assessment at 24 hours and at 3 months after their
presenting event to the emergency department. The National Institutes of Health
Stroke Scale (NIHSS)106, modified Rankin scale131'132 and the Questionnaire to
validate stroke-free status (QVSFS)109 were completed by the neurologist at 3
months. At 3 months, after reviewing all clinical and imaging information, the final
diagnosis of the presenting event was made and the potential mechanism assigned
using the TOAST133 classification.
9.1.4. Statistics
Patient characteristics are shown using standard descriptive statistics. The
association between the presence or absence of a rMTT delay (PWI lesion) was
assessed for all baseline characteristics. Logistic regression modeling using
backward elimination was used to identify predictors of a PWI lesion. Only a main
effects model is presented because of the relatively small cohort.
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9.2. RESULTS
A total of 69 classical TIA patients were enrolled between May 2002 and
December 2003. Median duration of symptoms was 90 minutes (range 5-1380
minutes). 27 patients were female (39%). In 56 of the patients (81%) the symptoms
had resolved by the time of the beginning of the MRI scan.
In 7 (10.1%) patients who had an MRI performed the PWI sequence was not
completed or was not able to be interpreted due to movement artefact or other
technical difficulties. These patients were included in the analysis of patients without
a PWI lesion. In 21(33.9%) patients there was evidence of a delay in the MTT map.
See results in table 5. Mean time to MRI scan was 9.2 hours in patients with a PWI
lesion and was 13.6 hours in patients without a PWI lesion (p=0.04).
In 12 patients (57.1%) this perfusion abnormality was present despite having
their neurological symptoms completely resolved (see figure 13). In 14 patients
(66.7%) who had MTT abnormalities seen there was a larger area ofMTT delay than
the size of the DWI lesion (mismatch).
In a multivariable model, occlusion is the most important predictor of PWI
lesion or not (p=0.011). This is true even after accounting for time and whether the
patient has clinically resolved or not.
Nearly all patients (66/69, 95%) had a modified Rankin score (mRS) of 0 or 1
at 3 months. Of the three patients who had a mRS > 1, all had resolved clinically by
the time of the MRI scan but two had a persistent PWI abnormality. Two of these
patients had recurrent strokes (one who had a PWI abnormality and one who did
not). Among patients with complete clinical resolution of symptoms at the time of
MRI, 21% had a PWI lesion.
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9.3. DISCUSSION
In this study we have found that despite many patients having transient
symptoms a significant proportion ofTIA patients have perfusion abnormalities
evident on MRI (as defined by the MTT map). The only factor to be predictive of a
perfusion abnormality in a multivariable analysis was the presence of a vessel
occlusion on MRA.
Previous work imaging TIA patients within the first month after their
symptoms using SPECT162 has shown that despite the event being relatively distant
most of the patients had some abnormality in perfusion or in their response to
acetazolamide. The authors concluded that these patients may be at risk for sub¬
clinical ischaemia. There is also a case series reported where 3 patients with
completely resolved TIA's were given a midazolam challenge and their neurological
deficits returned.163 One explanation for the recurrence in symptoms would be
persistent sub-clinical ischaemia. No perfusion studies were performed in this case
series. There is growing evidence that TIA is not a benign condition especially in the
first 48 hours after the event. The presence of persistent ischaemia in the absence of
symptoms is one possible mechanism for recurrent stroke after TIA.
In our analysis we found that vessel occlusion was the only factor that
predicted the presence of a PWI lesion and that this was not necessarily correlated
with the clinical assessment of symptom resolution. Work described in Chapter 7164
has suggested that patients can have mild neurological symptoms in the presence of a
middle cerebral artery occlusion and still achieve good neurological outcomes.
Similarly, in this study nearly all patients had an excellent outcome. This is different
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than much of the previous literature. One major difference in this study is that all
patients were admitted to hospital and were seen by a stroke neurologist at baseline,
24 hours and at any neurological deterioration. This meant that the diagnosis of TIA
or stroke was as correct as it could be and patients with minimal symptoms that
might be considered normal by a non stroke expert were not classified as a TIA. This
may be the reason for the low event rate in these patients.
Importantly, a discord between clinical complete resolution and the presence
of a PWI abnormality was observed in this study. Further study using quantitative
perfusion techniques165 to define benign oligemia166 is required to determine if
symptom resolution is associated with benign oligemia alone and therefore could be
used to differentiate tissue at risk of infarction.
There are limitations to our study. This was performed at 3 Tesla and with the
higher signal to noise ratio theoretically we may identify more areas of subtle
abnormality than if the studies had been done at 1,5T. We also used the MTT map
and this parameter can overestimate the amount of tissue at risk in a given patient.167
Some other groups have used thresholding techniques when looking at the MTT
map. We felt that any evidence of perfusion abnormality in this population of
patients was of interest.
Although these patients were scanned quickly, in most patients their
neurological deficits had completely resolved by the time of scanning. It is well
known that patients with severe carotid stenosis can have MTT delays on imaging;
however this does not appear to be the only explanation for these deficits since many
of these patients did not have evidence of large artery disease. It is also theoretically
possible that the prolonged MTT seen in these patients is caused by metabolic
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depression. The delay to MR scanning was longer in TIA patients whose scans to not
show evidence of a PWI abnormality suggesting that the proportion of TIA patients
with perfusion abnormalities may well be much higher. The delay to MR scanning
was longer in TIA patients whose scans did not show evidence of a PWI abnormality
suggesting that our results may underestimate the true proportion of TIA patients
with perfusion abnormalities.
In a high proportion of TIA patients there is evidence of persistent active
disease by way of perfusion abnormalities despite the rapid resolution of symptoms.
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Figure 13: A. DWI lesions shown by arrows at baseline in a TIA patient
whose symptoms of left sided weakness resolved within 30 minutes. B.
shows the MTT abnormality at baseline. C. hyperintense region in right MCA
territory on the FLAIR at 30 days. This is in the area of the abnormal
perfusion abnormality at baseline. The patient was clinically asymptomatic.
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PWI lesion No PWI lesion
(n=21) (n=48)
Age 69(12) 67(12) 0.35
Male gender 52% 65% 0.43
NIHSS 0(0-1) 0(0-0.5) 0.23
(median)
Onset-to-MRI 552 (103) 817(72) 0.04
time
ICA disease 14% 2% 0.081
Resolved 57% 92% 0.002
Occlusion 48% 8% <0.001
Table 5: Comparison of clinical factors in patients with PWI lesions and those
who do not have evidence of PWI lesion (univariate analysis). The last
column shows p values. Variables (age, gender, blood pressure, baseline
serum glucose, baseline NIHSS score, diabetes mellitus, atrial fibrillation,
ischaemic heart disease, cholesterol, antiplatelet treatment, past stroke or
TIA, smoking status) that were not significant at p < 0.05 are not shown.
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Chapter 10: Discussion and summary
10.1. ASPECTS; a rating scale for acute ischaemic changes,
can be reliably interpreted by experienced physicians in real
time.
Since the publication of the NINDS tPA trial in 19957 and licensing of tPA in
North America the treatment of stroke as an acute medical emergency has
blossomed. Initially the non contrast CT was used to screen patients for evidence of
hemorrhage only. Technology has advanced and the state of the art CT scanners in
use in large centres can give images minutes after the patient arrives in the
emergency room. Not all patients benefit from tPA and indeed some suffer harm.
Thus many stroke physicians have tried to find ways to refine the current criteria for
thrombolysis. The European Co-operative Acute Stroke Study (ECASS) trials59
identified the importance of early ischaemic change seen on CT in predicting benefit
with intravenous thrombolysis. Patients were eligible only if there was ischaemia
involving less than one third of the middle cerebral artery (MCA) distribution
territory. This method has proved not to be reliable and the Alberta Stroke Program
Early CT Score (ASPECTS) was developed by the team here in Calgary to attempt to
reliably quantify ischaemic changes. ASPECTS has been shown to predict functional
outcome and the risk of symptomatic hemorrhage in tPA treated stroke patients.65
However, the ability to reliably identify ischaemic changes on CT in real time is a
more difficult task than that performed in a perfect research environment. In Chapter
3 we show that ASPECTS is reliable when performed in real time by a group of
individuals experienced in scoring ASPECTS. The reliability is good, but not
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excellent however, even in experienced hands. This perhaps emphasizes the
difficulty in basing any treatment decisions on a particular ASPECTS score.
10.2. ASPECTS can be applied to the CTA-SI in acute stroke
and identifies more abnormal tissue than the NCCT alone.
Until recently ASPECTS has been a scale for assessing ischaemic change on the
NCCT in acute stroke. Recently it has been applied to MRI's performed in acute
stroke - DWl"3 and PWI168. In Chapter 4 we show that ASPECTS can be applied to
CTA-SI reliably and that on average more damage is identified. Unfortunately the
numbers were too small to look at response to treatment in patients who have a large
mismatch between the NCCT ASPECTS and the CTA-SI ASPECTS. This is an
important area since CT Angiography is much more widely available than MRI.
10.3. ASPECTS on CTA-SI may be useful in patients with a
normal NCCT.
The usefulness of early ischaemic changes in acute stroke appears to be
twofold. Firstly, the use of early CT changes can help reduce the risk of symptomatic
intracranial hemorrhage with tPA treatment if you withhold treatment from those
with extensive ischaemic damage. There is also however a proportion of patients
who present with one of the many "stroke mimics" (e.g. seizure, migraine, functional
etc.) and sometimes a completely normal scan can leave the physician with
diagnostic uncertainty. In this case further neurovascular imaging can be useful.
There are a variety of ways that the diagnosis of acute ischaemic stroke can be
confirmed. Transcranial Doppler (TCD) could be used to identify an occluded vessel,
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MRI if available quickly could be used to screen for stroke or as we have shown CT
Angiography can be helpful. The advantages ofCTA in acute stroke is that it is fast,
cheap and the images are able to be interpreted immediately. In Chapter 4 we show
that CTA-SI can help identify the presence of hypoperfusion confirming a stroke in a
number of cases where the NCCT was considered normal. This may be especially of
help in smaller centres where the expertise at interpreting acute ischaemic changes
may not be as prevalent.
10.4. Estimating mismatch between DWI and PWI with the
human eye is not reliable
In chapter 5 we found that quantifying mismatch by the human eye is
reproducible, but not reliable among observers. This has implications for basing any
potential treatments based on this method. The error that we found in this study was
around ± 20% making any treatment decisions made on a certain percentage of
mismatch problematic. This would potentially be a major problem if the late
treatment of patients without a certain percentage mismatch would increase the rate
of hemorrhage. Further research is needed in this area and trials such as EPITHET95
may answer some of the uncertainties.
10.5. TIA and Minor stroke patients can be triaged with an acute
MRI scan performed in the first 24 hours.
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Patients who have completely resolved or who have minimal symptoms seem
the perfect target for secondary prevention. However despite current best medical
therapy a substantial proportion of minor stroke and TIA patients will go on to have a
stroke within the next 90 days13 In Chapter 6 we show that 50 % of patients do not
have any evidence of an acute DWI lesion on an acute DWI-MRI. These patients are
at a low risk of having a recurrent stroke. It is not cost effective or efficient to admit
all TIA and minor stroke patients to hospital for investigation and treatment. This
result if confirmed may allow many patients to be discharged home and investigated
as an in- patient. We also discovered that patients with evidence of a DWI lesion and
a vessel occlusion were at a very high risk of recurrent events (around 30%). Further
secondary prevention trials should possibly concentrate only on patients with
evidence of ischaemia on MRI. It may actually be that a substantial proportion of
DWI negative patients do not have any ischaemia to begin with.
10.6. Do the results from Chapter 6 and 7 contradict each
other?
About a third of patients who have thrombolytic therapy withheld because of
initially mild symptoms have been found to be dead or dependent at 3 month follow
up/discharge.'2 The work in chapters 6 and 7 addressed this issue and asked the
question whether acute imaging of the cerebral arteries using MRI helps to predict
which patients are likely to deteriorate or have a further event. In chapter 7 we
studied 5 patients with acute stroke and mild symptoms (NIHSS < 3) in whom MRI
scan showed a middle cerebral artery occlusion, a group anecdotally felt to be at high
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risk of deterioration if no recanalization is obtained. None of the patients were
treated with thrombolysis and yet all were independent at 3 months. On the other
hand, in chapter 6 we studied 15 patients with minor stroke or TIA who on MRI had
both a DWI lesion and evidence of a vessel occlusion, and showed that by 3 months
around 40% had had a recurrent event and 4 (27%) were dead or dependent. Part of
the explanation for these seemingly different findings may be that the populations
studied were different. In chapter 7, we studied only patients with MCA occlusion
whilst in chapter 6 we also included patients with ICA, ACA and PCA occlusion
(There were 15 patients with vessel occlusion; 7 ofwhich were MCA occlusions (3
Ml occlusions and 4 M2 branch occlusions), the other vessel occlusions included 5
ICA, 1 ACA and 2 PCA's). However, 3 (43%) of the 7 patients in chapter 6 who had
MCA occlusions were dead or dependent at 3 months. We do not have
recanalization data on most of these patients at 24 hours so cannot comment on
whether vessel recanalization led to good outcome. Lastly, it must also remain
possible that the optimistic results of chapter 7 - that no patients with mild symptoms
and an MCA occlusion were dead or dependent - were a chance finding due to the
small number of patients studied. Regardless of the explanation, it is important to
note that 4 (57%) of the 7 patients with MCA occlusion in chapter 6 were
independent at 3 months. Taken with the findings of chapter 7, it therefore still
seems reasonable to conclude that, for many patients with minor stroke or TIA and
MCA occlusion, the prognosis remains surprisingly good. The question that remains
is how to identify which patients are likely to do well and which are likely to do
badly. This would allow potential therapies to be established to prevent poor
outcome. If we could identify which patients in this population are likely to have a
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poor prognosis then potentially thrombolysis with tPA or even novel therapies may
be offered to these patients.
10.7. TIA and Minor stroke patients have a high rate of
clinically silent recurrent ischaemic lesions
Previous work looking at a cohort of all stroke patients admitted to a general
hospital showed an unexpectedly high rate of recurrent ischaemia.14' This work
suggests that despite current methods for secondary prevention stroke patients still
have a high risk of ischaemia. In Chapter 8 we looked at a different population of
patients - TIA and mild stroke patients. We found a much lower rate than Kang et al
did suggesting that the populations of patients may be different. However the rate of
around 10% is still significant, especially in these patients with such mild symptoms.
Further secondary prevention trials need completed to reduce the accumulation of
ischaemic disease. Importantly we found that patients with multiple baseline lesions
had a higher risk of recurrent ischaemic lesions. These patients are at high risk for
recurrent ischaemia and clearly need further treatment than the current standard of
care.
10.8. A high proportion of TIA patients show perfusion
abnormalities despite resolution of symptoms
It is now well known that patients with TIA's are at high risk for recurrent
events. We found in chapter 9 that despite most of these patients having completely
resolved in terms of their symptoms in a surprisingly high proportion of patients
114
there was evidence of ongoing perfusion abnormalities. This was seemingly
unrelated to large artery disease, although the numbers are small. Importantly, a
discord between clinical complete resolution and the presence of a PWI abnormality
was observed. Further study using quantitative perfusion techniques is required to
determine if symptom resolution is associated with benign oligemia alone.
Potentially, quantitative perfusion techniques could be used to differentiate tissue at
risk of infarction from tissue that is not.
There are many potential mechanisms for recurrent stroke including re-
embolisation, complete occlusion, and other hemodynamic factors etc. This work
further emphasises that there is a subgroup of TIA patients who have truly active
disease. This seems comparable to unstable angina in the cardiology world. Further
research is needed to clarify whether these patients are at increased risk for recurrent
events.
10.9. The use of MR imaging for clinical trial enrolment
There is much interest at the moment into optimising anti-platelet therapy in
stroke prevention. Results from the CURE169 trial where the addition of clopidogrel
to standard therapy with aspirin showed benefit in reducing recurrent events. Recent
results from the MATCH trial170 showed a non-significant difference in reducing
vascular events, but the risk ofmajor bleeding was increased. It may be possible
using MR imaging to identify patients for future stroke prevention trials. For
example only TIA and minor stroke patients with evidence of a DWI lesion at
baseline could be enrolled, thereby not exposing low risk patients to possible harm.
Recurrent lesions seen on follow up MRI may also be used as a marker for treatment
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effect. The continued accumulation of ischaemic disease may require more intensive
therapy (with statins, antihypertensives etc.).
10.10. Summary
Acute stroke and TIA patients are a diverse group of patients and new
imaging techniques are being used to identify patients at risk for recurrent events
and/or response to thrombolysis.
ASPECTS is a rating scale for ischaemia in the middle cerebral artery
territory and has been used until now with studies completed retrospectively or with
consensus scores. We showed that ASPECTS can be rated by an experienced group
of raters reliably in real time. This is important since a scale is not useful in clinical
practice unless it is reliable in real time and not just in a research setting. ASPECTS
was also reliable when applied to CTA-SI. ASPECTS performed on CTA-SI
identified more evidence of ischaemic change than the NCCT alone. This may be
helpful in identifying populations for thrombolysis.
Minor stroke and TfA are not benign conditions. The presence of an acute
DWI lesion on MR1 heralds patients at high risk for recurrent events and functional
dependence. We also found that some patients with vessel occlusion and minor
stroke and TIA are at high risk of a poor outcome. Elowever, interestingly these are a
surprising number of patients with minor stroke and vessel occlusion who have a
good outcome. Follow up MRI also can identify patients who are accumulating
ischaemic damage despite best medical therapy. Despite minor symptoms these
patients have a 10% risk of new ischaemia as seen on MRI at 1 month, around 50%
of these ischaemic events are clinically asymptomatic. MR Imaging of TIA has
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showed that approximately 50% of these patients have evidence of ischaemic
damage despite resolution of symptoms. We looked at perfusion imaging in TIA
patients and found that many patients had evidence of perfusion abnormalities
despite resolution of symptoms. Further work is necessary to see the clinical
implication of this.
CT and MR Imaging in acute stroke and TIA patients can identify new
potential populations of patients for future therapeutic trials of stroke prevention and
treatment.
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Consent Form
This consent form, a copy of which has been given to you, is only part of the process of
informed consent. It should give you the basic idea of what the research is about and what your
participation will involve. If you would like more detail about something mentioned here, or
information not included here, you should feel free to ask. Please take the time to read this
carefully and to understand any accompanying information.
INTRODUCTION
The Acute Stroke Team in Calgary comprised of investigators from the Calgary Health Region
and the University of Calgary is conducting studies involving diagnostic imaging in acute stroke.
Described below are the tests that may be performed while you are in hospital. You are being
asked to allow investigators at the University of Calgary and the Calgary Health Region to
perform these tests and have access to the images and your health records to collect
information that may be helpful in the understanding of acute stroke. The studies are
complementary to regular care and may aid in the understanding of your stroke. Each study
may or may not benefit your immediate care. Each carries minimal or no risk to you. Please
review the consent form below with us.
1. 3 Tesla Magnetic Resonance Imaging (3T MRI)
1.1. Introduction
MRI provides a safe, non-invasive method of obtaining diagnostic information about the
structure and function of any designated part of the body, in this case the brain. The
purpose of the 3T MR study is to determine if MR imaging helps in the treatment of acute
stroke patients.
1.2. Procedures
The 3T MR Study involves baseline imaging as soon as possible after stroke onset.
Additional scans may be suggested as part of a serial follow up study, which may include a
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repeat scan following your stroke. Each time a series of MR images will be taken which
could include non-standard imaging sequences. Routinely a contrast agent (gadolinium) is
given by intravenous injection to better visualize structures in the brain. Which could include
non-standard imaging sequences.
1.3. Risks and Discomforts
There are no known long-term effects from MR. MR machines use strong magnets to
take pictures, if you have an implanted pacemaker or other metal device, you are unable to go
in a MR machine. You will be carefully screened for this and we will also ask you to remove
your watch, any hearing aid and other metal items. A very small minority (less than 1%) of
patients will experience mild tingling, muscle twitching, or claustrophobia. Very rarely, a patient
will experience an allergic reaction to the contrast agent. Commonly such reactions are mild
and do not require treatment. Extremely rarely, they are life threatening and require intensive
treatment.
2. Transcranial Doppler Ultrasound (TCP)
2.1. Introduction
Occlusion of the arteries in the brain is the most common cause of stroke. Ultrasound
imaging may be used to obtain information on the flow of blood within the brain. The
purpose of the TCD project is to determine if TCD helps in the treatment of acute stroke
patients.
TCD is an approved technique in Canada and the United States. TCD provides a safe, non¬
invasive method of obtaining diagnostic imaging about the brain's arteries.
2.2 Procedures
The TCD will be done as soon as possible after the onset of your stroke symptoms. A TCD
examination takes approximately 15 minutes. An ultrasound probe is placed on your head
while you lie on a bed or sit in a chair. Where indicated, additional exams or continuous
monitoring may be suggested as part of the study.
2.3 Risks and Discomforts
There are no known harmful effects or discomfort associated with this technology.
3. Computed Tomographic Contrast Studies-Anqioqraphy (CTA) and Perfusion (CTP)
3.1 Introduction
February 12, 2004-Version # 7.0
Foothills Medical Centre, 1403-29th Street NW, Calgary Alberta T2N 2T9, Tel: (403) 944-1800
APPENDIX 1: Consent and Information Diagnostic St
UNIVERSITY OF
calgary health region CALGARY
tdies in Acute Stroke
"oothills Medical Centre
CT Angiography and CT Perfusion provides a safe, non-invasive method of obtaining blood
flow in the arteries of the brain in relation to possible brain death associated with lack of
blood flow. CT Angiography gives information about which blood vessels are affected by
the stroke. CT Perfusion gives us absolute measurements of blood flow to various portions
of the brain. This assists radiologists in analysing blood flow of stroke victims—where the
speed of diagnosis and treatment is often the primary factor in determining the extent of
recovery. CT Perfusion generates colour images that allow physicians to evaluate the extent
of brain tissue damage quickly and to plan treatment. CT Perfusion has received approval
for clinical use.
3.2 Procedures
After the standard CT of the brain, a bolus of intravenous contrast is given to the patient
(in the absence of any contraindications). The head is scanned again to develop pictures of the
blood vessels supplying the brain. This CT Angiography can give us information into which
blood vessels are blocked. If it is felt clinically relevant a second bolus of contrast will be
administered and the area of brain of interest will be scanned. This CT Perfusion study will give
us absolute levels of blood flow to various areas of the brain.
3.3 Risks and Discomforts
Some patients may experience mild side effects, which usually pass quickly but may last a
few minutes. Mild side effects may include warmth, burning sensation, nausea, vomiting,
taste alteration, hives and itching. These usually require no treatment or respond quickly to
medication. In rare occasions, life threatening or even fatal reactions may occur.
There is an increased dose of radiation used with CT Angiography and Perfusion as
compared to a normal CT scan. The risk from the increased dose of radiation is very small.
4. VISION - Vascular Imaging of acute Stroke for Identifying predictors of clinical
Outcome and recurrent ischaemic eveNts
4.1. Introduction
VISION is a comparison research study investigating three neurovascular imaging
methods: Magnetic Resonance Imaging (MRI); Computed Tomography (CT) and Transcranial
Doppler (TCD) ultrasound. The objective of the study is to determine which combination of
imaging modalities (tests) should be used in various clinical situations allowing for the most
optimal (successful) outcome. You will be one of approximately 720 patients participating in this
study. Your clinical participation in the study will last approximately 90 days.
4.2. Procedures
You will receive the same standard care given to all stroke patients including a careful
physical examination. Your doctor will determine medications and tests used for you standard
care.
All baseline imaging will be completed as soon as possible after stroke onset. If you
agree to participate in this study and you meet all of the entry criteria, your doctor will continue
to collect information about you during your hospitalisation, and for approximately 90 days after
your stroke. Most of the information collected will be performed during the first 24 hours of this
study. Additional MRI/CT scans or TCD may be performed. You will be asked to return for follow
up visits at 30 (+/-14) days and 90 (+/-14) days after your stroke. During each evaluation a
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series of neurological exams will be performed. Baseline imaging may include 2 or more
modalities to be determined by the treating physician:
Baseline: Possible
Additional Scan:




















A Study Nurse or Study Investigator will call you by telephone after you are home. You
will be asked questions if you have experienced any new stroke/TIA symptoms. These phone
calls will take approximately 5-10 minutes each, and would take place at 6 months, 12 months,
18 months and 2 years.
4.3. Risks and Discomforts
Please see risks described in sections 1.3, 2.3, and 3.3.
5. MONITOR- Modelling the EvolutiON of Infarctinq Tissue in the setting of Occlusion
and Recanalization
5.1. Introduction
MONITOR is a research study investigating brain lesion evolution (change) and
outcomes between patients who have recanalization (opening of the artery) and those who
have no recanalization of the MCA occlusion (blockage). The ultimate aim is to develop imaging
indicators, which will help identify stroke patients who could benefit from treatment interventions.
You will be one of approximately 24 patients participating in this study. Your participation in this
study will last approximately 90 days.
5.2. Procedures
You will have already received diagnostic imaging of the brain (CT and MRI) and brief
sound wave ultrasound test of the blood vessels (arteries) in the brain (TCD) to determine that
he blockage is located in the middle cerebral artery (MCA).
Additional MRI/CT scans or TCD may be performed 12 (+/- 6) hours, 24(+/-6) hours,
7(+/-2) days, and 30(+/-10) days following your stroke. Routinely a contrast agent (gadolinium)
is given by intravenous injection to better visualise the structures in the brain. Each scan takes
about 30 minutes.
A TCD examination will be done as soon as possible after the onset of your stroke
symptoms and lasts for 15 minutes. In some cases, a lightweight head frame will be positioned
using Velcro and a knob for adjusting allowing for repeated exams every 30 minutes for up to 8
hours after stroke onset. The head frame will be loosened between examinations. Repeat TCD
exams will be performed after the 12 and 24 hour MRI studies.
If you agree to participate in this study and you meet all entry criteria, your doctor will
continue to collect information about you during your hospitalization and for approximately 90
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days after your stroke. Most of the information will be collected during the first 24 hours of this
study. You will be asked to return for follow up visits at 7(+/-2) days, 30(+/-14) days and 90 (+/-
14) days after your stroke. During each evaluation a series of neurological exams will be
performed.
5.3. Risks and Discomforts
Please see risks described in sections 1.3, 2.3, 3.3.
6. Serial CTP- Development of CT based Indices of Tissue Viability and Infarction in
Acute Stroke
6.1. Introduction
Serial CTP is a research study that involves CT scanning and measuring brain blood
flow and brain blood volume in stroke patients. The objective of the study is to investigate
whether measuring brain blood volume and brain blood flow will help predict patient clinical
outcome. You will one of 80 patients participating in this study. Your participation in this study
will last approximately 7days.
6.2 Procedures
You will receive the same standard of care that is given to all stroke patients including a
careful physical examination. You will have already received diagnostic imaging of the brain (CT
and/or MRI) on admission to the hospital.
Additional CT scans at 24 (+/-6) hours and 7 (+/-3) days will be performed following your
stroke. The head is scanned again to develop pictures of the blood vessels supplying the brain.
This can give us information into which blood vessels are blocked. You will receive a bolus of
intravenous contrast (in absence of any contraindications). Each CT scan takes approximately
10 minutes to perform. If you agree to participate in this study, and meet all the entry criteria,
your doctor will continue to collect information for 7 days during your hospitalisation. You will
not have to return for follow up visits as part of the study, but you will need to return as part of










Please see risks described in sections 1.3, 2.3, 3.3
7. ONQ-2506 MRI Substudv
Primary Investigator: Dr Michael Hill, Tel (403) 944-8065
Study Sponsor: Ono Pharma USA, Inc.
7.1. Introduction
To participate in the ONO-2506 MRI Substudy you must have provided informed consent for the
main ONO-2506 Study (Protocol # 2506/INT0104). If you choose to participate in the MRI
Substudy, two special MRIs will be performed during the Evaluation Phase (on Study Day 1)
and again approximately one-month later (at the study site). The purpose of this Substudy is to
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assess the differences between 1,5T and 3.0T stroke MRI among patients randomized to the
ONO trial. There will be a total of 10 patients enrolled at this site.
7.2 Procedures
Evaluation Phase (on Study Day 1):
If you are eligible to enter the study, you will be randomly assigned (like flipping a coin) to one of
two groups. You will receive either a 1.5T stroke MRI first or a 3.0T stroke MRI first immediately
followed by a second stroke MRI on the other magnet or shortly after the first intravenous
infusion of the investigational medication. All patients would therefore have both a 1.5T and a
3.0T stroke MRI. Group A would be defined as stroke patients who had 1,5T MRI followed by a
3.0T MRI and group B patients would be defined as patients who had a 3.0T MRI followed by a
1.5TMRI.
Each time a series of MR images will be taken which could include non-standard imaging
sequences. Routinely a contrast agent (gadolinium) is given by intravenous injection to better
visualize structures in the brain. Which could include non-standard imaging sequences.
Month 1:
You will receive both a 1.5T stroke MRI first and a 3.0T stroke MRI at approximately 1 month
following your stroke.
7.3-Risks and Discomforts
Please see risks described in sections 1.3.
8. CT versus MRI in hemorrhage detection- The detection of hemorrhagic
transformation in acute stroke.
8.1. Introduction
CT vs. MRI is a research study that is evaluating the advantages of Magnetic
Resonance (MR) imaging as compared to Computed Tomography (CT) imaging in detecting
bleeding (hemorrhage) in the brain following a stroke. This research is trying to determine
whether: 1) MR imaging can be used instead of CT to determine blood in the brain following
stroke 2) detect leaky blood vessels within the brain at the time of stroke to predict future
bleeding. You will be one of 60 patients participating in this study. Your participation in this
study will last approximately 72 hours.
8.2 Procedures
You will receive the same standard of care that is given to all stroke patients including a
careful physical examination. You will have already received diagnostic imaging of the brain (CT
and/or MRI) on admission to the hospital.
You will undergo a repeat CT scan at 72 hours (+/- 24 hours) after your stroke. You will
receive intravenous contrast (as long as you have had no reactions to same prior). This will take
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approximately 10 minutes. An additional MRI scan will also be performed at 72 hours (+/- 24
hours) following your stroke. This will take approximately 30 minutes to complete. Information
will be collected for about 72 hours during your hospitalisation. You will not have to return for
follow up visits as part of the study, but you will need to return as part of your care after your
stroke at 90 days.
8.3-Risks and Discomforts
Please see risks described in sections 1.3, 2.3, 3.3
PROCEDURES
In addition to standard stroke follow up, you may be asked to return to the hospital for further
follow up assessments. This may include a physical/neurological exam; stroke scales and
possibly repeat imaging. We will try to coordinate these visits to occur at the same time.
POSSIBLE BENEFITS
The information obtained may be helpful in planning and monitoring your therapy. The study
will not affect the quality of your care. Participation may help future patients suffering from
stroke.
COMPENSATION
In the event that you suffer as a result of participating in this research the Calgary Health
Region, the University of Calgary or the researchers will provide no compensation. You still
have all your legal rights. Nothing said here about treatment or compensation in any way alters
your right to recover damages.
VOLUNTARY PARTICIPATION
Your participation in these research studies is voluntary. You can decide not to participate, and
you are free to withdraw from this study at any time without penalty or loss of benefits and your
withdrawal will not jeopardise your medical care at this facility. You may also decide to
participate in only parts of this series of diagnostic studies.
INFORMATION COLLECTED
The information (clinical and imaging) collected will remain confidential in the hands of the
investigators.
The images collected through this research will be stored confidentially in a computerized
database that is protected by a "firewall". A database allows researchers to assess the
information collected at a later time for further analysis and secondary publications to help
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expand the knowledge bases regarding stroke. You have the right to contact the researchers at
any point in time and have your images and information removed from the database. Also, in
the event of your death, your next of kin may also request to have your images deleted and
destroyed.
The results of these studies may be presented at meetings or in publications; however, your
identification will not be disclosed. Images may be used by industry but your identification will
be kept confidential. None of the investigators have a financial conflict of interest in asking you
to participate.
CONSENT
Your signature on this form indicates that you have understood to your satisfaction the
information regarding participation in the research project and agree to participate as a subject.
In particular, you have understood to your satisfaction the study purpose, risks and benefits,
how the information will be used and that you are under no obligation to participate and may
withdraw at any time.
In no way does this waive your legal rights nor release the investigators, sponsors, or involved
institutions from their legal and professional responsibilities. You are free to withdraw from the
study at any time without jeopardising your health care. Your continued participation should be
as informed as your initial consent, so you should feel free to ask for clarification or new
information throughout your participation. If you have further questions concerning matters
related to this consent form, please contact:
3T MRI, CTA and CTP: Dr. Robert Sevick @ (403) 944-1800
TCD: Dr. Andrew Demchuk @ (403) 944-8287
If you have any questions concerning your rights as a possible participant in this research,
please contact Pat Evans, Associate Director, Internal Awards, Research Services, University of
Calgary at (403) 220-3782.
I wish to have the following tests:
0 3TMRI 6CTA 0 VISION 0 Serial CTP study 0CTvs.MRI
0 TCD 0 CTP 0 MONITOR 0 ONO-2506 MRI Substudy hemorrhage detection
1. Patient or Surrogate/Legal Guardian
/ /20
Participant's signature day month
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/ /20
Surrogate's signature Name Relationship day month
2. Investigator
I certify that I have explained the above procedure(s) and in my opinion,
understands its nature, risks and consequences.
/ /20




Witness' signature Witness' name day month
A copy of this consent form will be made available for you.
For Inclusion for Pediatric Studies:
The investigator will, as appropriate, explain to your child the research and his or her
involvement, and will seek his or her ongoing cooperation throughout the project.
SURROGATE CONSENT
Because your illness made it impossible for you to participate in the informed consent process,
the proxy (delegate) consent of your next of kin (legal surrogate or guardian) was obtained on
your behalf. Your surrogate believed you would have wished to participate in this research if
you had been able to express your own opinion at the beginning of the research.
As noted earlier, the process of informed consent must be continuous throughout a research
project. This means that patients have the right to change their minds and, therefore, must be
given opportunities to voice any changes they might wish. In your situation, you now have the
opportunity to agree or disagree with the decision made by your surrogate to enroll you in this
project.
If you agree with the decision made by your surrogate to enroll you, your signature will affirm
your participation in this study. If you do not agree with the decision made by your surrogate to
enroll you, you may withdraw at anytime from the study.
Your signature on this form indicates that you have understood to your satisfaction the
information regarding participation in the research project and agree to participate as a subject.
In no way does this waive your legal rights nor release the investigators, sponsors, or involved
institutions from their legal and professional responsibilities. You are free to withdraw from the
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study at any time without jeopardizing your health care. Your continued participation should be
as informed as your initial consent, so you should feel free to ask for clarification or new
information throughout your participation.
Please check the appropriate box(es) to indicate your decision:
□ I do agree with my surrogate's decision
□ I do not agree with my surrogate's decision
□ I wish to remain in the study




Witness' Signature Witness' name
_/ /20
DD/MM/YY
A copy of this consent form will be made available for you.
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□ Right □ Left
BP in ER triage
/
Time started h
Dose of IV tPA = mg
□ 0.9 mg/kg or n 0.6 mg/kg
Treated with IA
rtPA
□ yes □ no
Time
started








trial □ yes □ no
Name of trial: IfTIA,
length of
symptoms
□ Hypertension □ High cholesterol
□ Atrial fibrillation (at any time) □ Previous TIA/Stroke
□ Valvular heart disease □ <3/12
□ Recent MI (<3/12) □ Diabetes
□ Known CAD/ischaemic heart dx □ Allergy to Contrast Dye
□ Known CHF □ Patient on Glucophage
□ Sub-therapeutic INR □ Renal failure
□ On anti-platelet therapy □ Hx of cancer
□ Known carotid disease □ None of the above
□ Current smoker
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APPENDIX 3: NIH Stroke Scale Patient Initials: FMC #
o Baseline o 24hours (+/- 6 hours o 30 days o 3 months
from baseline NIHSS) (+/- 2 weeks) (+/- 2 weeks)
la
Level of 0 = Keenly responsive
Consciousness: 1 = Not alert, but arousable by minor stimulation to obey, answer or respond
2 = Not alert, requires repeated stimulation to attend, or is obtunded and requires strong or
painful stimulation to make movements (not stereotyped)
3 = Responds only with reflex motor or autonomic effects or totally unresponsive, flaccid
lb LOC Questions: 0 = Answers both question correctly 1 = Answers one question 2 = Answers neither question
lc LOC Commands: 0 = Performs both tasks correctly 1 = Performs one task 2 = Performs neither task
2 Best Gaze: 0 = Normal
1 = Partial gaze palsy. This score is given when gaze is abnormal in one or both eyes, but
where
forced deviation or total gaze paresis is not present.
2 = Forced deviation, or total gaze paresis not overcome by the occulocephalic maneuver.
3 Visual: 0 = No visual loss 1 = Partial hemianopia 2 = Complete hemianopia
3 = Bilateral hemianopia (blind including cortical blindness)
4 Facial Palsy: 0 = Normal symmetrical movement
1 = Minor paralysis (flattened nasolabial fold, asymmetry of smiling)
2 = Partial paralysis (total or near total paralysis of lower face
3 = Complete paralysis of one or both sides (absence of facial movement in the upper and lower
face)
5 Motor Arm: 0 = No drift, limb holds 90 (or 45) degrees for full 10 seconds
1 = Drift, limb holds 90 (or 45) degrees, but drifts down before full 10 seconds; does not hit bed
2 = Some effort against gravity, limb cannot get to or maintain (if cued) 90 degrees
3 = No effort against gravity, limb falls
4 = No movement A= Amputation or joint fusion, explain:
5a Left:
5b Right
6 Motor Leg: 0 = No drift, leg holds 30 degrees position for full 5 seconds
1 = Drift, leg falls by the end of the 5 second period but does not hit bed
2 - Some effort against gravity; leg falls to bed by 5 seconds, but has some effort against gravity
3 = No effort against gravity, leg falls to bed immediately
4 = No movement A= Amputation or joint fusion, explain:
6a Left:
6b Right
7 Limb Ataxia: 0 = Absent If present circle each limb YES or NO
1 = Present in one limb Right Arm: YES NO Left Arm: YES NO
2 = Present in two limbs Right Leg: YES NO Left Leg: YES NO
Amputation or joint fusion, explain:
8 Sensory: 0 = Normal; no sensory loss
1 = Mild to moderate sensory loss; patient feels pinprick is less sharp or is dull on the
affected side; or there is a loss of superficial pain with pinprick but pt is aware
2 = Severe to total sensory loss; patient is not aware of being touched in the face, arm & leg
9 Best Language: 0 = No aphasia, normal
1 = Mild to mod aphasia: some obvious loss of fluency or facility of comprehension without
significant limitation on ideas expressed or form of expression.
2 = Severe aphasia: all communication is through fragmentary expression; great need for
inference, questioning , and guessing by the listener carries burden of communication
3 = Mute, global aphasia; no usable speech or auditory comprehension
10 Dysarthria: 0 = Normal
1 = Mild to mod: patient slurs at least some words and at worst, can be understood with some
difficulty
2 = Severe: patient's speech is so slurred as to be unintelligible in the absence of or out or a
proportion to any dysphasia, or is mute/anarthric
9 = Intubated or other physical barrier, explain:
11 Extinction and 0 = No abnormality
Inattention (Neglect) 1 = Visual, tactile, auditory, spatial, or personal inattention or extinction to bilateral
Simultaneous stimulation in one of the sensory modalities
2 = Profound hemi-inattention or hemi-inattention to more than one modality. Does not
recognize own hand or orients to only one side of space
12a Distal Motor 0 = Normal
Function: (Arm) A = At least some extension after 5 seconds, but not fully extended. Any movement of the
Fingers which is not command is not scored




IF NIHSS = 0, then please document length of symptoms: (at 24hrs only)
**(For 24 hours only)**
TOTAL:
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APPENDIX 4 : Modified Rankin Scale and Barthel Index
Modified Rankin Scale Information provided by:
o Baseline o 1 month o 3 months
(pre-stroke) (+/- 2 weeks) (+/- 2 weeks)
O 0 = Asymptomatic
o 1 = No significant disability, despite symptoms; able to carry out all usual duties and activities
n 2 = Slight disability; unable to carry out all previous activities but able to look after own affairs
without assistance
o 3 = Moderate disability; required some help, but able to walk without assistance.
o 4 = Moderately severe disability; unable to walk without assistance and unable to attend to own bodily
needs without assistance.
o 5 = Severe disability; bedridden, incontinent and requiring constant nursing care and attention.




o 1 month o 3 months
Score
1. Feeding 0 = unable





0 = unable; no sitting balance
5 = major help (one or two people; physical); can sit
10 = minor help (verbal or physical)
15 = independent
3. Grooming 0 = needs help with personal care
5 = independent face/hair/teeth/shaving(implements provided)
4. Toilet Use 0 = dependent
5 = needs some help, but can do something alone
10 = independent (on and off, dressing, wiping)
5. Bathing 0 = dependent
5 = independent (or in shower)
6. Mobility 0 = immobile
5 = wheelchair independent, including corners
10 = walks with help of one person (verbal or physical)
15 = independent (but may use aid eg. cane)
7. Stairs 0 = unable
5 = needs help (verbal, physical, carrying aid)
10 = independent
8. Dressing 0 = dependent
5 = needs help but can do about half unaided
10 = independent (including buttons, zips, laces etc.)
9. Bowels 0 = incontinent (or needs enemas)
5 = occasional accident (once/wk)
10 = continent
10. Bladder 0 = incontinent, or catheterised and unable to manage alone
5 = occasional accident (once/wk max)
10 = independent
TOTAL SCORE
Date (dmy): / / Time: Signature:





Symptom Side (of BODY) = Baseline/Follow-Up =
Scoring the CT Scan Aspect Score
Yes No Score the ischemic hemisphere
Hemorrhage 1=normal; 0=abnormal Score
Type (Ph1 ,PH2, HI1.HI2) Caudate
HMCA sign Lentiform
HSFBS "dot" sign Insula
Sylvian fissure Br Sign Internal Capsule
ACA Lesion MCA 1
PCA Lesion MCA 2
Brai nstem/cerebellar MCA 3
Eye Deviation (L, R, MCA 4
LAEL, LAER, C, NS) MCA 5
Comments: MCA 6
total (add up)
HMCA = hyperdense middle cerebralartery sign; hsfbs = hyperdense sylvian fissure branch artery sign; aca = anterior
cerebral artery ischemia pca = posterior cerebral artery ischemia
EYE Deviation: L=left; R=right. LAEL = lone abducting eye left; LAER = lone adbucting eye right; o central; ns=not
scorable
Scan is of good quality to assess ASPECTS: □ Yes DNo
ECASS 1995 Hemorrhage Rating Criteria:
HI1 = small petechial along the margins of infarct
HI2 = more confluent petechial within the infarcted volume, without space-occupying effect
PH1 = blood clot not exceeding 30% of infarcted volume with mild space-occupying effect
PH2 = dense clot exceeding 30% of the infarct volume with significant space occupying effect
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APPENDIX 6: CT Interpretation Form - Baseline
Patient Initials: Patient #: FMC Exam Date / /
DD MMM YYYY
Exam # Start Time: h
CTA □ Completed- □neck, □ circle ofWillis
□ Not Completed
Symptom Side: □ Right □ Left □ Aphasia
Interpretation by (list name) Rater o 1 o 2
(Tick more than box where relevant, comment where )
1. NCCT quality □ Good-little movement,
□ Intermediate-some movement,
□ Poor-majority unreadable due to movement
2. ASPECTS scoring: Plain CT
Score 1 for normal or 0 for abnormal:




□ Internal capsule □M5
□Ml Gm6
Total=
Based on NCCT is there evidence of an acute stroke? OYes QNo
If yes, OAnterior Circulation □Posterior Circulation
3. Presence of remote ischaemic change:
Tick location:
Location ACA MCA PCA Cbell/brainstem Small vessel Disease
Right
Left
(If CTA not performed stop here; ifCTA performed proceed to next page)














APPENDIX 6: CT Interpretation Form - Baseline
□ Completed -Oneck, □ circle ofWillis
□ Not Completed
Quality of CTA scans □ Good-little movement, minor venous filling
□ Intermediate-some movement,
□ Poor-majority unreadable due to movement/missed
bolus
Left Right
Normal ■I flow Occl Partial
Occl





ICA □ □ □ □ □ □ □ □ □ □
If ICA: □ □ □ □ □ □ □ □ □ □
Cervical
Petrous □ □ □ □ □ □ □ □ □ □
Cavernous □ □ □ □ □ □ □ □ □ □
Supraclino □ □ □ □ □ □ □ □ □ □
id
MCA1 □ □ □ □ □ □ □ □ □ □
proximal
MCA1 □ □ □ □ □ □ □ □ □ □
distal
MCA2 □ □ □ □ □ □ □ □ □ □
Distal □ □ □ □ □ □ □ □ □ □
MCA
ACA □ □ □ □ □ □ □ □ □ □
PCA □ □ □ □ □ □ □ □ □ □
VA □ □ □ □ □ □ □ □ □ □
BA □ □ □ □ □ □ □ □ □ □
0ccl= Occlusion, Partial occl= thrombus or stenosis partially occluding vessel, utd -unable to determine.
Is extra-cranial ICA stenosis present? QYes QNo
If yes, to what percentage? □<50% □50-70% Q>70% QNear occlusion
Have you identified an occlusion? QYes QNo
Blood Pool - Score 1 for normal or 0 for abnormal cerebral blood flow, X for unable to judge. Only
score what you consider to be acute lesions on affected side:








Has the CTA changed your level of confidence regarding the presence of an acute stroke?
□ No □ yes - If yes: □ Increased confidence in likelihood of stroke
or □ Decreased confidence in likelihood of stroke
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APPENDIX 6: CT Interpretation Form - Baseline
5. Perfusion ASPECTS - Score 1 for normal or 0 for abnormal cerebral blood flow, X for unable to
judge. Only score what you consider to be acute lesions on affected side:




□ internal capsule □ m5
□mi □m6
Total=
Approx MTT delay (main lesion to non-lesion)= ms or Qunable to estimate
In your opinion is there a visible MTT map lesion? QYes QNo
Based on CTP is there evidence of an acute stroke? QYes QNo
If yes, QAnterior Circulation □Posterior Circulation
Date (dmy): / / Time: Signature:
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APPENDIX 7:MRI Interpretation Form - Baseline
APPENDIX 7: MRI Interpretation form - Baseline
Patient Initials: Patient VISION#: FMC
Exam Date / / Exam #
Symptom Side: □ Right □ Left □ Aphasia
Interpretation by (list name)




□Normal or fill in below:
□Solitary □Multiple
□ Left □Right
Territory ACA MCA PCA Vertebrobasilar
Left
Right
d) Tissue type/s affected? □Cortical Grey Matter □White Matter QBasal Ganglia
□brainstem nuclei or tracts □Cerebellum
e) Age of lesion(s)?
□hyperacute □acute □ subacute
(hyperacute=no evidence on T2; acute=some T2 & hypointense on ADC; subacute=normalised ADC)
f) DWI/ADC ASPECTS - MCA territory Score 1 for normal or 0 for abnormal, X if unable to judge because of
scan quality. Do not score remote lesions.
Side rated: If bilateral lesions fill in both rows otherwise rate the affected side
Region Caud Lentif Insula Int cap Ml M2 M3 M4 M5 M6 Total
Left
Right
2. MRA Circle of Willis:
a) Intracranial Pre-Gd: □Normal □Abnormal □unable poor quality
Site ofOcclusion:
Side ICA MCA ml MCA m2 ACA PCA Basilar PICA Vert
Right
Left
b) Intracranial Post-Gd: □Normal □Abnormal □ unable poor quality
Site of Occlusion:
Side ICA MCA ml MCA m2 ACA PCA Basilar PICA Vert
Right
Left
Site of Stenosis/partial occlusion:




APPENDIX 7:MRI Interpretation Form - Baseline
c) Comments (e.g. There appears to be flow beyond a thrombus in the MCA or Decreased signal intensity in MCA but no occlusion seen implying
extracranial stenosis)
d) Hyperintense vessel on FLAIR? UNo










4. a) FLAIR/T2 Are there remote infarcts on these studies? DYes QNo
Location ACA MCA PCA Cbell/brainstem
Right
Left
b) Small Vessel Disease rating
□Little □moderate □ large
5. PWI Gradient Echo hypointensities: □none □solitary □multiple
6. Relative perfusion maps
a) rMTT lesion present? QYes QNo □unable quality poor
Vascular territory:
Side MCA ACA PCA Vert/Basilar
Right
Left
b) rMTT ASPECTS - Score acute MTT delay in MCA and not remote infarcts. 1 for normal or 0 for
abnormal, X if unable to judge. □Right □Left
Region Caud Lentif Insula Int cap Ml M2 M3 M4 M5 M6 Total
Aspects
In event of hyperperfusion with reduced transit time comment
c) □ MTT>DWI mismatch □ DWI=MTT matched □DWI>MTT reverse mismatch
d) rCBV: oligemic lesion present: QYes QNo Qunable quality
Vascular territory




APPENDIX 7:MRI Interpretation Form - Baseline
e) rCBV ASPECTS Score acute CBV changes in MCA. 1 for normal or 0 for oligemia, X if unable to judge
and indicate if hyperemia (t) and/or oligemia (i) present in each region
□Right □Left
Region Caud Lentif Insula Int cap Ml M2 M3 M4 M5 M6 Total
Aspects
t or I
f) For oligemic regions only: □mismatch □ matched Qreverse mismatch
7. a) Quality of scans: □ Good □ Intermediate □ Poor
b) If Artefact present: □Movement □Susceptibility □Ghosting □Other
8. Summary
a) acute/subacute ischaemic stroke seen? QYes QNo
If no: □Normal scan QOther pathology
b) Suspected etiology: QLacunar □central embolic source □Carotid atheroslcerosis
□vertebrobasilar atherosclerosisQdissection □Source indeterminate
□Other
9.Lesion likely to enlarge? QYes QNo
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Appendix 8: Modified Questionnaire for Verifying Stroke-Free Status
(QVSFS)
Sum Score: = to 0 (negative- TIA/stroke free), Sum Score between 1-8 (positive-
o 30 days o 3 month f/u o 6month f/u o 1 year f/u o 18 mon f/u o 2 year f/u
(+/- 2 weeks) (+/- 2 weeks) (+1-2 weeks) (+/- 4 weeks) (+/- 4 weeks) (+/- 4 weeks)
telephone telephone telephone telephone
Since your stroke/TIA:
1. Have you had another stroke or TIA (transient ischemic attack)?
□ Yes □ No
If yes, date:
2. Have you had sudden painless weakness on one side of your body?
□ Yes □ No
3. Have you had sudden numbness or a dead feeling on one side of your body?
□ Yes □ No
4. Have you had sudden painless loss of vision in one or both eyes?
□ Yes □ No
5. Have you suddenly lost one half of your vision?
□ Yes □ No
6. Have you suddenly lost the ability to understand what people are saying?
□ Yes □ No
7. Have you suddenly lost the ability to express yourself verbally or in writing?
□ Yes □ No
Yes = 1, No = 0,
Score:
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Appendix 9: Final Diagnosis and TOAST form
Has the 3 month follow up been completed?
□ If "YES", complete Final Diagnosis and Etiology sections
□ If "NO" explain: □ Patient re-location
□ Unable to contact patient
□ Patient deceased
Final Diagnosis:










□stroke of other determined etiology
□stroke of undetermined etiology.
Was carotid endarterectomy performed? aYes □ No Date:
Has the pt had a new cerebrovascular event within the 90day window frame? aYes n'No
□TIA
Date of 1st event: Total number ofTIA's OR
□Stroken Ischaemic □ Hemorrhagic
Date of 1st event:
If new event: nMild □ Moderate □ Severe
OR
Is this a progression of the original stroke? □ Yes □ No nCan't say
If "Yes", please describe:




Appendix 10 : Patient Initials:
30day MRI follow up
Patient #: FMC
VISION MRI Interpretation form - 30 day follow up
Patient Initials: Patient VISION#: FMC number
30 day Exam Date / / Exam #
Initial day Exam Date __/ /
Symptom Side: □ Right □ Left □ Aphasia
Interpretation by: Date Assessed(D/M/Y) _ _/ /
1. New discrete DWI lesions - in comparison to baseline scan,
none □
a) Lesion: □Solitary □Multiple
b) Side/s: □Left □Right
c) Vascular territory/ies involved (4 as many as app y):
Territory ACA MCA PCA Vertebrobasilar
Left
Right
d) Tissue type/s affected by new lesions?
□Cortical Grey Matter □White Matter □Basal Ganglia □brainstem nuclei or tracts
□Cerebellum
e) Age of new lesion(s)?
□hyperacute (no evidence on T2)
□acute (some T2 & hypointense on ADC)
□subacute normalized ADC
2. FLAIR/T2 ASPECTS- of the baseline acute lesion. 1 Normal, 0 abnormal X unable
Region Caud Lentif Insula Int cap Ml M2 M3 M4 M5 M6 Total
Left
Right
3. MRA Circle of Willis in comparison with baseline:




















Appendix 10 : Patient Initials:





4. Based on the MRI is there hemorrhage? OYes □No
Is it in the original infarct? OYes QNo
ECASS rating:
□ HI1 (small petechiae)
□ HI2 (more confluent petechiae)
□ PHI (30% of the infarcted area with some mild space-occupying effect)
□ PH2 (>30% of infarcted area & significant space-occupying effect; or clot remote from original infarct)
5. Quality of 30 day scans: □ Good □ Intermediate □ Poor
IfArtefact present: □Movement □Susceptibility □Ghosting □Other
6. Summary:
Normal Scan: Qyes Qno
If no: □ Other pathology □ evolving stroke Qnew stroke
If new stroke:
1. □ Normal baseline MRI, new lesion at follow up
2. □ New lesion in area of perfusion abnormality at baseline
3. □ New lesion not in area of perfusion abnormality at baseline, but in same vascular territory.
4. □ Different artery altogether
7. Other pathology or comments please (limit free text)
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Appendix 11 : Statement of contribution to work
The collection of data for these imaging studies was carried out between May
2002 and May 2004 in the Department of Clinical Neurosciences in the University of
Calgary except for the data in Chapter 7 which was collected before I arrived in the
department. In chapter 4, 18 patients were enrolled by physicians from the
Departments of Radiology and Neurology, Massachussetts General Hospital,
Harvard Medical School, Boston. I was a clinical research fellow employed in this
department between August 2001 and March 2004 under the supervision of Dr.
Andrew M. Demchuk; subsequently since March 2004 I have been employed as a
Neurology resident at the University of Calgary, Alberta, CANADA. I performed all
analyses between summer 2003 and autumn 2004.
I organized the overall prospective multimodal imaging study and was project
officer on the Canadian Institutes of Health research (CIHR) grant for the study. I
designed the consent form and all the data collection forms - follow up,
demographics, imaging etc. I also obtained ethical approval for the study. I validated
all the clinical data that was inputted into the data base for accuracy and checked all
the final diagnoses/TOAST classification for each patient.
At the time ofwriting there were a total of 298 patients enrolled into the
VISION study as a whole. Out of 298 patients I personally enrolled 74 patients and
completed follow ups on 85 patients. The rest of the enrolling was completed by my
colleagues in the Calgary Stroke Program. This was a prospective cohort study and
individual hypotheses were tested independently. There are no sample size
calculations in this thesis due to the fact that this was an observational study and was
not testing a drug or treatment effect. I also acknowledge the help of the Clinical
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Appendix 11 : Statement of contribution to work
trials nurses for their help in maintaining follow up on such a large number of
patients. Karyn Fischer RN was key in being a point of contact for patients in follow
up. The patients described in Chapter 6 were enrolled into a previous imaging study.
I enrolled none of these patients, but developed the hypothesis, analyzed the results
and wrote the manuscript.
The projects were chosen in advance and each one was individually analyzed
while enrolling continued. This meant that there are differing numbers of patients in
each chapter. I planned all the analyses including the statistical analysis. I was
responsible for the day to day running of the imaging projects and contacted patients
who defaulted from follow up and visited patients in Nursing homes to gather 3
month clinical outcomes.
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